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Abstract 
 
World wide the number of people living with renal or liver transplants is growing due to the 
increase in prevalence of end stage renal disease and end stage liver disease which neccesitate 
transplantation. Life long immunosuppression is needed for transplant recipients to prevent graft 
rejection and or death. Whilst the immunosuppression can significantly improve patient and 
graft survival it comes at a cost to the healthcare services. It is therefore, important that the 
immunosuppression used in clinical practice is supported by both clinical and cost effectiveness 
evidence. 
 
The aim of this thesis is to evaluate the clinical and economic impact of immunosuppression 
therapy in the treatment and management of adult renal and liver transplant recipients based on 
author's published research. Healthcare systems across the world are now placing greater 
importance on optimising their finite resources in demonstrating clinical and cost effectiveness 
of treatments. A number of health authorities such as the United Kingdom(UK), National 
Institute of Health and Care Excellence (NICE) have implemented methodologies guiding 
resource allocation decisions through formal health technology assessment (HTA). Clinical and 
economic evidence generation and synthesis reflecting current clinical practice can help to 
inform HTA decisions which impacts patients access to medicines. 
 
This thesis presents and critically appraise eight peer reviewed publications to demonstrate the 
clinical and economic impact of immunosuppression therapy in adult renal and liver transplant 
recipients. Each publication updated and or contributed to new knowledge in the field. The 
thesis highlights how the eight publications formed a cohesive body of evidence which can be 
used by policy makers to inform the development and or updating of clinical and 
reimbursemsent guidelines which ultimately impact product adoption and patient accesss to 
immunosuppressive medicines. 
 
The clinical effectiveness of immunosuppression was explored through systematic literature 
reviews, meta-analysis and indirect treatment comparison to establish the efficacy and safety of 
the different interventions used in post renal and liver transplant. The outputs from the clinical 
effectiveness together with relevant data from other sources was used to develop economic 
models to assess the cost effectiveness of immunosuppression. An assessment of the budget 
impact of immunosuppression in post renal transplant was also examined. 
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Based on this research prolonged release tacrolimus was shown to be clinically and economically 
more effective than immediate release tacrolimus the current standard of care. The thesis 
concluded that tacrolimus remains the cornerstone of renal and liver post transplant 
immunosuppression while also highlighting the strengths and limitations of the current research 
and making recommendations for future studies. 
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Glossary of Terms 
 
Term Definition 
Absolute risk reduction The difference in event rates between two groups (one subtracted from the 
other) in a comparative study 
Confidence interval The range within which the ‘true’ values  size of effect of an intervention are 
expected to lie with a given degree of certainty  
Cost-effectiveness analysis An economic evaluation that compares alternative options for a specific 
patient group looking at a single effectiveness dimension measured in a non-
monetary (natural) unit. It expresses the result in the form of an incremental 
cost-effectiveness ratio. 
Cost –utility analysis is a type of cost-effectiveness analysis in which the (incremental) cost per 
quality-adjusted life year (QALY), is estimated 
Generalisability The degree to which the results of a study or systematic review can be 
extrapolated to other circumstances, particularly routine healthcare situations 
in clinical practice 
Heterogeneity A term used to illustrate the variability or differences between studies in the 
estimates of effects. 
Meta-Analysis Statistical analysis that integrates results from two or more studies providing a 
single numerical value of the overall treatment effect for that group of studies 
Odds Ratio The odds of the probabilityof an event occurring compared to the event not 
occurring in a particular group. The odds ratio is the ratio of the odds 
between two groups 
Probabilistic Sensitivity Analysis 
(PSA) 
Is a technique used in economic modelling that allows the modeler to quantify 
the level of confidence in the output of the analysis  in relation to uncertainty 
in model inputs 
Propensity Score Matching (PSM) is a statistical technique that attempts to reduce the possible bias associated 
with confounding variables 
Quality-adjusted life year (QALY) The QALY is a single measure of health related quality of life that takes into 
account both the quantity and quality of life provided by the intervention. 
Random Effects Model A model that assumes that the treatment effects of all included studies are part 
of a distribution of treatment effects that fall along a range of values 
Relative risk the ratio of risk in the intervention group to the risk in the control group 
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Chapter 1: Introduction 
 
1.1 The burden of End Stage Renal Disease and End Stage Liver Disease 
 
End Stage Renal Disease (ESRD) and End Stage Liver Disease (ESLD) are both chronic and 
irreversible conditions which represent a major public health burden. ESRD is the irreversible 
final stage of chronic kidney disease (CKD) which can result in death if not treated by either 
transplantation or dialysis. Worldwide, the number receiving renal replacement therapy (dialysis 
or renal transplantation) is estimated at more than 1.4 million, with incidence growing by 
approximately 8% annually [Schieppati and Remuzzi, 2005].  
 
Due to the scarce epidemiological data in RRT. The most recent incidence data could only be 
sourced at a country and regional level. The Reseau, Epidemiologie, Information, Nephrologie 
(REIN) report [2010] stated that in terms of incidence of  RRT in France in 2010, a total of 
9,439 subjects with ESRD started renal replacement therapy corresponding to a crude annual 
incidence rate of 149 pmp. It should be noted that whilst this data represent the most current 
data it is nonetheless from a country level and hence cannot be extrapolated to other healthcare 
systems across the world. Nevertheless, this report provides a more recent reference for 
incidence of RRT. At a regional level the European Renal Association–European Dialysis and 
Transplant Association (ERA-EDTA) registry in 2013 reported a total of 72 933 started RRT for 
ESRD resulting in an overall incidence of 112 pmp [Kramer et al., 2013].This incidence rate is 
lower than the French data reported in 2010 which could indicate the variation across countries 
and over time. 
 
On the other hand, ESLD is when the liver has been damaged to the point that it cannot 
perform its normal functions. Unlike ESRD were patients can have dialysis with ESLD the only 
hope of long-term survival is transplantation. The global prevalence of ESLD ranges from 4.5% 
to 9.5% of the general population and it is estimated that more than fifty million people in the 
world, of the adult population, would be affected with chronic liver disease [Lim and Kim 2008].  
 
Both ESRD and ESLD are serious illnesses with significant health consequences in terms of 
decreased health related quality of life (HRQoL), increased morbidity and mortality [Mathers et 
al., 2006; Go et al., 2004; Goicoechea et al., 2005]. In addition, the treatment and management of 
ESRD and ESLD is associated with significant health resource consumption and high cost 
  
10 
 
treatment options [Ruhl et al., 2013; Go et al., 2004; Goicoechea et al., 2005]. For example in 
Canada, less than 0.1% of the population has ESRD; however, the disease generated direct 
health-care costs of $1.3 billion in the year 2000. The amount of direct spending per person with 
ESRD was much more than the average spending per person for all health-care conditions 
[Zelmer, 2007]. Adding indirect morbidity and mortality cost brings the total burden associated 
with ESRD to $1.9 billion in the Canadian healthcare system [Zelmer, 2007]. In the United 
States direct costs associated with the management of ESLD in 2004 was estimated to be $2.5 
billion [Ruhl et al., 2013]. Therefore, ESRD and ESLD places significant clinical and economic 
burden on healthcare services and society.   
 
Transplantation is a treatment of choice for both ESRD and ESLD which can lead to 
improvements in HRQoL, graft and patient survival and lower longer-term costs [Winkelmayer 
et al., 2002; Wolfe et al., 1999]. However, lifelong regimen of immunosuppressive medication is 
required for transplant recipients to prevent graft rejection and or death. 
 
The immunosuppressive therapies needed to prevent rejection come at a cost as they account for 
most of the long-term costs of post transplantation management [Ruhl et al., 2013]. Despite the 
growing number of people living with renal and liver transplants and economic pressure on 
healthcare systems. Health economic evaluations in transplantation on immunosuppression are 
limited. Also clinical and reimbursement guidelines in liver and renal transplant are based on 
dated clinical evidence. My research has focused on updating the clinical evidence base and 
generating data on economic evaluations of immunosuppression therapy in adults with renal or 
liver transplantation. 
 
Morden healthcare is placing great importance on demonstrating clinical and economic 
effectiveness of treatments. The data and methodology used in such Health Technology 
Assessments (HTAs) is critically important as it affects whether a treatment is made available to 
patients. From a period when the choice of immunosuppressive agents was limited, there have 
now emerged a number of immunosuppressive agents. Consequently, the choice of 
immunosuppressant to be used in clinical practice should be supported by up to date clinical and 
economic evidence reflecting current clinical practice.  
 
The growing number of patients living with renal or liver transplants necessitating lifelong 
immunosuppression and economic pressure on healthcare systems requires efficient allocation of 
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resources. Evidence based healthcare decision is built on sound clinical and economic 
evaluations. Given the out dated clinical evidence and limited economic studies in this field. This 
thesis will focus on evaluating the clinical and economic impact of immunosuppressive therapy 
in adults with renal or liver transplants based on author's published research. 
 
The thesis presents eight papers, for which the present author was a co-author as is normal 
practice in health economics and outcomes research which is typically multidisciplinary. In 
addition to research design and analysis the present author played a critical and leading role in 
conceiving the research questions and project management of all the research studies and 
subsequent publications. The eight papers presented as part of this thesis were chosen from 
fourteen papers co-authored by present author covering period from 2012 to 2017. The thesis 
presents a critical commentary of the eight papers in the context of the rationale for publication 
of each paper, highlighting the uniqueness, methodologies, implications and contribution to 
literature for each paper. In addition, the thesis describes and appraises methodologies used, 
compare and contrast results from other studies that used clinical and cost effectiveness 
approaches in renal and liver transplant immunosuppression therapy.  
 
1.2  Aims of the thesis   
 
The overall aim of the thesis is to demonstrate the clinical and economic impact of 
immunosuppressive therapy in the treatment and management of adult renal and liver transplant 
recipients based on authors published research. 
 
The specific aims of the thesis are: 
 
1. Describe the methods used in establishing the clinical and economic impact of 
immunosuppression therapy in adult renal and liver post-transplantation. 
 
2. Evaluate the extent to which the research met requirements in terms of its strengths and 
limitations. 
 
3. Critically appraise the contribution of each study to knowledge in the field. 
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1.3  Structure of thesis 
 
The first two chapters introduce the thesis and provide a background on the burden of ESRD 
and ESLD, treatment and management of post renal and liver transplantation with 
immunosuppression therapy. The articles included in the thesis are grouped into three different 
categories and presented in chapters 3 to 5. The thesis provides a critical review of each study 
and an appraisal of how the studies could have been approached differently. Finally, chapter 6 
provides a summary of the thesis, make conclusions and recommendations for future research. 
 
Chapter 1: provided the overall aims and an overview of the topics to be covered in more depth 
throughout the thesis. 
 
Chapter 2: discusses the background to the burden of ESRD and ESLD, treatment and 
management of post renal and liver transplantation with immunosuppressive therapy. 
 
Chapter 3: examines the clinical effectiveness of immunosuppression therapy in the modern era 
of renal and liver transplantation. Systematic literature reviews, indirect treatment comparison 
and meta-analyses comparing the safety and efficacy of immunosuppressive therapy in renal and 
liver transplantation are introduced and an explanation of how they add to previous research is 
provided. Strengths, limitations and potential applications of this research are discussed. 
 
Chapter 4: demonstrates the cost effectiveness of immunosuppressive therapy in renal and liver 
transplantation from a UK, NHS payer perspective. A critique of health economic modelling in 
renal and liver transplantation is provided. 
 
Chapter 5: reviews the budget impact analysis of immunosuppressive therapy in renal transplant 
from a UK, NHS payer perspective. The importance of this research to patients, payers and 
policy makers is discussed. 
 
Chapter 6: provides a key summary of the research and conclusions highlighting implications 
for patients, clinical practice, healthcare policy and recommendations for future research. 
 
The next chapter will give a background overview to the burden of ESRD and ESLD, treatment 
and management of post renal and liver transplantation with immunosuppressive therapy. 
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Chapter 2: Background 
 
2.1 Introduction 
 
Chapter 1 has outlined the thesis rationale and aims focused on demonstrating the clinical and 
economic impact of immunosuppresion therapy in adult renal or liver post transplantation. The 
present chapter aims to provide an overview background in terms of definitions, prevalence, 
clinical and economic burden of ESRD and ESLD which neccesssitate transplantation. Current 
treatment and management of post renal and liver transplantation with immunosuppression 
therapy will be examined including guidelines and challenges to optimising patient outcomes. 
 
2.2 Definitions of End Stage Renal Disease and End Stage Liver Disease 
 
2.2.1 Definition of End Stage Renal Disease 
 
Chronic kidney disease (CKD) is irreversible and progressive. It is defined as either kidney 
damage (proteinuria, haematuria or anatomical abnormality) for ≥3 months or a glomerular 
filtration rate (GFR) <60 ml/min/1.73m2 measured on at least 2 occasions during ≥3 months 
[National Collaborating Centre for Chronic Conditions, 2008]. The Renal National Service 
Framework (NSF) classifies CKD into five stages, defined by evidence of kidney damage and 
level of renal function as measured by GFR (ml/min/1.73m2)[Department of Health, 2005]. A 
patient with stage 5 CKD (kidney failure GFR <15 ml/min/1.73m2) has a life threatening 
serious disease and requires renal replacement therapy (RRT) in order to maintain life. RRT 
refers to either regular dialysis treatment or renal transplantation. Stage 5 disease is also referred 
to as end stage renal disease (ESRD). End-stage renal disease occurs as the irreversible final stage 
in chronic kidney disease (CKD) when the kidneys are no longer able to function properly, 
leading to patient mortality, unless managed by dialysis or renal transplantation [National 
Collaborating Centre for Chronic Conditions, 2008].  
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2.2.2 Definition of  End Stage Liver Disease 
 
Chronic liver failure, also called end-stage liver disease (ESLD), progresses over months, years, 
or decades. Most often, chronic liver failure is the result of cirrhosis, a condition in which scar 
tissue replaces healthy liver tissue until the liver cannot function adequately [Alqahtani, 
2012]. Patients with abnormal liver function who develop ascites, variceal hemorrhage, hepatic 
encephalopathy, or renal impairment are considered to have end-stage liver disease [Mazzaferro 
et al., 1996]. The main causes of ESLD include persistent alcohol misuse, hepatitis, sclerosing 
cholongatis and cirrhosis [Alqahtani, 2012].  
 
2.3 Prevalence, clinical and economic burden of ESRD and ESLD 
 
This section presents the prevalence, clinical and economic burden of ESRD and ESLD. 
 
2.3.1 Prevalence, clinical and economic burden of ESRD 
 
ESRD is a global health burden an independent risk factor for cardiovascular disease (CVD) and 
is associated with increased risks of premature mortality, and decreased quality of life. ESRD is 
associated with age-related renal function decline accelerated in hypertension, diabetes, obesity 
and primary renal disorders [Gansevoort et al., 2013].The overlap between ESRD, diabetes and 
CVD, as well as the increasing risk of ESRD with age, means that the public health impact of 
ESRD is likely to increase.  
 
Globally the incidence of ESRD is on the increase. Although varying considerably across 
countries, the annual incident rate of patients starting (RRT) is high, ranging from 150 to 400 per 
million population (pmp) in the Western world to around 50 pmp in poor countries where 
access to health care is limited [Jha et al., 2013].  There are nearly 700,000 people with ESRD in 
the United States corresponding to an annual incidence rate of 355 per million population (pmp) 
[Collins et al., 2014]. In the United Kingdom (UK) and in Europe, the average annual incidence 
of ESRD is 120,000 and 135,000, respectively [Steenkamp et al., 2011]. Table 1, below  shows the 
wide variation across regions in the population using and being initiated on RRT. 
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Table 1.1: Use and annual initiation of renal replacement therapy. 
 
Data are presented according to World Bank Regions, with High Income countries as 
comparators. 
Abbreviations: RRT–renal replacement therapy, pmp–per million population. Source: Anand et 
al., [2013]. 
 
In addition to increased cardiovascular events and overall premature mortality, ESRD is 
associated with significant healthcare resource use [Go et al., 2004; Goicoechea et al., 2005]. Life 
expectancy is reduced by as much as 10 to 15 fold in patients who have ESRD [Minino et al., 
2009; Bleyer et al., 1996]). Furthermore, patients with ESRD who are on dialysis have lower 
quality of life in comparison with the general population [Liem et al., 2007; Lumsdaine et al., 
2005].  
 
The annual cost per person on RRT is prohibitive ranging from USD $15,000 in Sub Saharan 
Africa to more than $80,000 in the United States [Collins et al., 2014; Arogundade and Barsoum 
2008; Swanepoel et al., 2013]. Over 2% of the total UK, National Health Service (NHS) budget is 
spent on renal replacement therapy for patients with established renal failure [National 
Collaborating Centre for Chronic Conditions, 2008]. 
 
2.3.2 Prevalence, Clinical and Economic Burden of ESLD 
 
Global prevalence of  ESLD  ranges from 4.5% to 9.5% of the general population [Melato et al., 
1993; Graudal et al., 1991; Lim and Kim 2008]. During 2001, the estimated worldwide mortality 
from ESLD was 771,000 people, ranking 14th and 10th as the leading cause of death in the 
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world and in developed countries, respectively [Mathers et al., 2006]. Deaths from ESLD have 
been estimated to increase and would make it as the 12th leading cause of death in 2020 [Murray 
and Lopez, 1997]. In Europe ESLD is responsible for 170,000 deaths per year [Blachier et al., 
2013].  
 
In addition to increased mortality ESLD also impacts patients' daily activities. Most patients with 
ESLD report significant impairment of their HRQoL [Afendy et al., 2009; Gutteling et al., 2006]. 
The degree of HRQoL impairment is dependent on the type of ESLD, patients with viral 
hepatitis C (HCV), primary biliary cirrhosis (PBC), and nonalcoholic fatty liver disease (NAFLD) 
seem to have more impairment [van der Plas et al., 2007]. A number of studies have reported that 
patients with HCV and PBC have significantly reduced HRQoL due to fatigue and depression 
[Afendy et al., 2009; Gutteling et al., 2006; Sobhonslidsuk et al., 2006]. 
 
The clinical and HRQoL burden of ESLD is further compounded by economic impact on 
healthcare services and societies. The overall cost of ESLD includes direct costs (drug,  liver 
transplantation and hospitalization costs) and indirect costs due to loss of work productivity and 
reduction in health-related quality of life (HRQOL) [Ruhl et al., 2013]. Direct and indirect 
financial costs associated with ESLD impose a considerable socioeconomic burden on health 
services and society [Iacobucci et al. 2012; Lee and Kyung-Rae, 2011; Ray et al. 2002]. In 2004, 
the direct costs of  chronic liver disease in the United States (US) were estimated to be $2.5 
billion, whereas indirect costs were estimated to be $10.6 billion[Ruhl et al., 2013]. Treatment of 
complications of ESLD including encephalopathy, variceal bleeding and the development of 
hepatocellular carcinoma (HCC) have all increased in frequency and expense over the past 
decade [Nathan et al., 2012; Neff et al., 2011; Nguyen et al., 2007]. ESLD due to chronic hepatitis 
B virus (HBV) and hepatitis C virus (HCV) that are refractory to treatment can progress to 
decompensated cirrhosis and HCC, resulting in high economic costs for public health services 
[van der Meer et al., 2012].  
 
The clinical, HRQoL and economic burden together with the increased mortality associated with 
ESRD and ESLD necessitates transplantation in order to ensure patient survival. 
2.4 Renal and Liver Transplantation 
 
Renal transplantation is regarded as the treatment of choice in patients with ESRD whose only 
alternative is frequent dialysis, a procedure which leads to significant morbidity, impaired quality 
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of life and greater mortality [Wolfe et al., 1999; UK Renal Registry, 2014]. In the UK, patient 
survival at ten years after a first renal transplant is 77.0% compared with 28.2% for dialysis 
[NHSBT 2014; Pruthia et al., 2012]. 
 
Equally, liver transplantation is now recognized as the treatment of choice for ESLD 
[Mazzaferro et al., 1996].The goals of liver transplantation are to improve patient survival and 
HRQoL since most patients with ESLD typically have poor quality of life due to several factors 
including fatigue, cachexia, pruritus, ascites, hepatic encephalopathy and variceal bleeding 
[Alqahtani, 2012]. Liver transplantation continues to mature, with advances in many surgical and 
medical aspects leading to improved survival rates. In the UK survival rates for liver 
transplantation are 91% for 1 year, 77% for 5 years and 59% at 10 years, with some patients 
living for 15–20 years after transplant [NHSBT, 2011]. This indicates that whilst short term 
survival has increased there is still an unmet need in long term survival. 
 
In addition to patient survival transplantation results in improved patient quality of life, increased 
independence and lower longer-term costs [Winkelmayer et al., 2002; Wolfe et al., 1999]. 
However, without lifelong immunosuppression, transplant recipients are at risk of graft rejection 
or loss, arising from immune processes directed at the transplanted organ. Lifelong regimen of 
immunosuppressive medication is therefore required for transplant recipients to prevent graft 
rejection and or loss, death or resumption of dialysis in renal transplantation. It is therefore, 
imperative that immunosuppression used in clinical practice should be based on its effectiveness 
in preventing organ rejection, optimisation patient survival and HRQoL afforded by renal or 
liver transplantation. The use of immunosuppression to optimise graft and patient survival will 
be explored in Chapter 3, of this thesis. 
 
2.5 Immunosuppression Therapy Current Treatment Options 
 
The ultimate goal of post-transplant immunosuppression is to effectively suppress the immune 
system, while minimizing post-transplant adverse events and toxicity. The calcineurin inhibitor 
(CNI) class of immunosuppressive drugs, tacrolimus and ciclosporin, has long been the mainstay 
of post-transplant immunosuppression. Since the CNIs were first approved for prevention and 
treatment of graft rejection, a number of new immunosuppressive agents have been developed 
with the goal of reducing the nephrotoxic effects that have been associated with the CNI class 
[Goring et al., 2014].  
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Among these newer agents licensed in the UK for kidney and or liver immunosuppression are 
the mammalian target of rapamycin (mTOR) inhibitor class, which includes sirolimus and 
evorolimus; and the selective co-stimulation blocker belatacept. Current treatment with 
immunosuppression typically constitutes of triple therapy with (1) primary immunosuppression 
with a CNI, m-TOR inhibitor or selective co-stimulation blocker; (2) an antiproliferative that is 
Mycophenolic acid or mycophenolate mofetil; and (3) a corticosteroid. This triple therapy is 
aimed at striking the right balance between effectiveness and toxicity. 
 
Immediate release tacrolimus and ciclosporin form the foundation of modern 
immunosuppressive therapy in renal and liver transplant recipients with tacrolimus being the 
standard of care (SoC). These two products have been reformulated specifically, ciclosporin was 
reformulated into a micro-emulsion (Neoral) and subsequently tacrolimus has been reformulated 
into a once-daily, prolonged-release (PR) formulation (Advagraf) from the twice-daily, 
immediate-release (IR)formulation (Prograf) [European FK506, 1994; US FK506, 1994; Otto et 
al., 1998 ; Loinaz  et al., 2001]. The introduction of these new formulations in particular once 
daily tacrolimus requires literature to reflect on the potential benefits of the once daily 
formulation in terms of adherence and impact on graft and patient survival. Also the old 
ciclosporin formulation is no longer used in clinical practice. Therefore, the clinical data in terms 
of systematic reviews and meta-analysis need to be updated to reflect the changes in 
formulations and potential implications on relative effectiveness. This thesis addressed this issue 
in Chapters 3 to 5 through reviewing author's publications based on clinical and cost 
effectiveness taking into account newer products, formulations and data from recent clinical 
trials to reflect modern transplant era. 
 
Immediate release tacrolimus is the SoC in the UK [NICE, 2004] and most parts of the world. 
Tacrolimus is also widely used in the USA for post transplantation immunosuppression see 
below table 2. As such the focus of this thesis will be predominantly on comparison of other 
immunosuppressive therapies with immediate release tacrolimus as the SoC in the treatment and 
management of adult renal or liver transplant recipients. 
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Table 2.2: Most frequently prescribed maintenance regimens at 1 and 2 years post-
transplantation in the US, 2003–2007 
 2003 2004 2005 2006 2007 
1 year post-transplant      
Tacrolimus + 
corticosteroids, % 
20.9 18.1 15.7 15.1 12.5 
Tacrolimus, % 30.1 28.3 28.6 26.5 28.5 
Tacrolimus + MMF/MPA, 
% 
13.7 15.2 18.1 22.1 25.0 
Tacrolimus + MMF/MPA 
+ corticosteroids, % 
14.1 15.5 16.8 17.4 15.2 
Cyclosporine + 
corticosteroids, % 
2.0 1.7 1.2 1.2 1.0 
2 years post-transplant      
Tacrolimus + 
corticosteroids, % 
13.8 12.1 9.7 9.1 ― 
Tacrolimus, % 37.9 36.0 35.9 35.6 ― 
Tacrolimus + MMF/MPA, 
% 
16.0 17.5 21.0 24.5 ― 
Tacrolimus + MMF/MPA 
+ corticosteroids, % 
9.4 10.0 10.9 10.1 ― 
Cyclosporine + 
corticosteroids, % 
1.4 1.0 0.8 0.7 ― 
MMF, mycophenolate mofetil; MPA, mycophenolic acid 
Source: Wiesner and Fung [2011]. 
 
2.5.1 Treatment Guidelines 
 
Published in 2004, currently under review the national guidelines for immunosuppression in 
adult renal transplant patients in England and Wales reported that tacrolimus should be 
considered as an alternative to ciclosporin when a calcineurin inhibitor is indicated as part of 
initial or maintenance immunosuppression in renal transplantation for adults [NICE, 2004]. This 
guideline has largely been adopted in liver in spite of no official NICE multiple technology 
appraisal in liver transplantation. 
 
International renal and liver transplantation bodies have developed clinical practice guidelines for 
the treatment and management of renal and liver transplant recipients. The Kidney Disease 
  
20 
 
Improving Global Outcomes [KDIGO, 2009] guidelines recommend using a combination of 
immunosuppressive medications including a CNI and an antiproliferative agent with or without 
corticosteroids in post renal transplantation. The guideline states that tacrolimus and 
Mycophenalate should be the first line CNI and antiproliferative respectively. The guideline also 
recommends that m-TORs should not be started until graft function is established and surgical 
wounds are healed. No mention is made of belatacept reflecting a need to update the guidelines. 
 
The European Association for the Study of the Liver [EASL, 2015] clinical practice guidelines 
state that CNI based immunosuppression is still the cornerstone of post liver transplant 
immunosuppression. The guidelines also state that tacrolimus results in better long term graft 
and patient survival. However, it does not distinguish between prolonged and immediate release 
tacrolimus formulations. Emerging data from routine clinical practice appear to indicate that 
prolonged release tacrolimus is more effective than immediate release tacrolimus in graft survival 
and hence guidelines should reflect this development [Adam et al., 2015]. 
 
It is clear that the reimbursement and clinical guidelines need to be updated to reflect current 
clinical practice including evidence on new products and formulations. This thesis will review the 
author's publications on clinical and cost effectiveness of existing products and formulations 
including those introduced after the publication of the [NICE, 2004] guidelines to ensure the 
data reflect current clinical practice in both liver and renal transplantation and therefore adding 
new knowledge to this area. 
 
2.6 Unmet Need 
 
Whilst Immunosuppressants can lead to significant improvements in HRQoL, patient and graft 
survival they are also associated with side effects such as hypertension, new-onset diabetes after 
transplantation (NODAT) and renal dysfunction due to nephrotoxicity. Studies have 
demonstrated that CNIs including tacrolimus the current SoC have a well characterized efficacy 
and safety profile in patients at risk of post-transplantation graft rejection. However, doses that 
result in tacrolimus exposure outside of the therapeutic range can result in an increased risk of 
rejection (with low tacrolimus concentrations) or toxicity (with high tacrolimus concentrations) 
[Kershner and Fitzsimmons 1996; Borobia et al., 2009; Taatz et al., 2001]. This poses a challenge 
in optimising graft survival. Adherence to immunosuppression has also been highlighted as a 
major contributing factor to long-term graft and patient survival. 
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Whilst the benefits of immunosuppression outweighs the adverse effects. Nephrotoxicity, 
adherence and within-patient variability are important factors that represent a significant unmet 
need in post-transplant immunosuppression with current standard of care which need to be 
explored in terms of their clinical and economic consequences. The next section will briefly 
evaluate the importance of within-patient variability in immunosuppression therapy. 
 
2.6.1 Within-Patient Variability  
 
Within-patient variability variously referred to as intra-subject, intra-individual or intra-patient 
variability, the term refers to day-to-day differences in either tacrolimus concentration or 
tacrolimus clearance in a given patient taking the same daily dose. The high within-patient 
variability in tacrolimus pharmacokinetics and the relatively narrow therapeutic index (NTI), 
necessitate the use of regular therapeutic drug monitoring (TDM) of whole-blood tacrolimus 
trough concentrations (i.e. the concentration immediately before taking another dose) to 
establish the appropriate dose for a given patient [Scott et al., 2003]. Within-patient variability is 
typically measured using the coefficient of variability (CoV), which is calculated by dividing the 
standard deviation of the trough concentration by the mean and expressing the result as a 
percentage [Kahan et al., 2000]. Any reduction in CoV would be likely to reduce the complexity 
associated with establishing a suitable dose, while potentially also improving patient outcomes by 
maintaining the whole-blood tacrolimus concentration within the therapeutic range which is 
critical for NTI drugs because there is little difference between toxic and therapeutic doses.  
 
Published evidence indicates that there is a relationship between high within-patient variability 
and poor clinical outcomes, specifically graft failure. Notably, Borra et al., [2010] published a 
retrospective analysis into the relationship between tacrolimus concentration variability and graft 
loss. The study found that significantly more renal transplant recipients with high within-patient 
variability had an increased risk of graft loss than those with low within-patient variability. 
 
The impact of within-patient variability will be explored in chapter 5, to evaluate the clinical 
differences that might exist between formulations and consequent economic effect. This data 
will provide new knowledge in this area and potentially influence the development of future 
clinical and reimbursement guidelines. The next section will examine adherence as an unmet 
need in renal and liver post transplantation.  
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2.6.2 Adherence 
 
Adherence is the degree to which a patient correctly follows the prescribed dose and interval of 
dosing [Chisholm et al., 2005]. Given the proven effectiveness of immunosuppressants in 
preventing post-transplantation graft rejection, patient adherence to the prescribed regimen 
becomes a critical factor in improving graft survival outcomes. However, adherence to 
immunosuppression represents a key challenge in renal and liver transplant recipients. The 
clinical consequences of non-adherence include accelerated renal function decline, increased risk 
for late acute rejection and increased risk of graft loss. Overall, non-adherence rates in renal 
transplant recipients are high. A review by Denhaerynck et al., [2005], reported that the weighted 
mean of self-reported non-adherence was 28%, but the prevalence of non-adherence in 
individual studies varied from 2% to 67% contributing to 16% of graft losses and 20% of late 
acute rejections. In liver transplant non-adherence rates are relatively lower compared to renal 
transplant however, it is still a significant problem increasing the risk of both acute and chronic 
organ rejection. A study by Burra et al., [2011] reported that the rate of non-adherence to 
immunosuppression amongst adult liver transplant recipients was 15–40%. 
 
 A 2007 meta-analysis reported that the risk of non-adherence to immunosuppressive regimens 
was highest in renal transplant recipients [Dew et al., 2007]. Several studies have since reported 
on various factors that can influence adherence in transplant recipients, including a 2012 study 
which showed that there is a strong inverse association between the number of 
immunosuppressive medications used by a transplant recipient and the proportion of patients 
who are adherent to therapy [Dharancy et al., 2012]. Furthermore, dosing frequency and regimen 
complexity have also been associated with reduced adherence [Weng et al., 2005].  
 
Given that twice-daily, immediate-release formulations still constitute the majority of 
immunosuppressant prescriptions; there is still a great unmet need in allograft recipients for 
reduced pill burden [National Health Service Business Services Authority, 2013]. One of the 
challenging clinical consequences of non-adherence is antibody mediated rejection (AbMR) with 
approximately 60% of late graft failures thought to be attributable to AbMR [Butler et al., 2004]. 
Although strict adherence to immunosuppressant medication is essential for the long-term 
survival of kidney and liver grafts, it has been shown as highlighted above that 
immunosuppressants are one of the most common groups of prescription drugs to which post-
transplant patients are non-adherent [Constantiner and Cukor, 2011] representing an area of 
unmet need.  
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Several studies have demonstrated that even minor variations from the prescribed 
immunosuppression are associated with an increased risk of poor outcomes for transplant 
recipients [Dharancy et al., 2012; Constantiner and Cukor, 2011; Maclean et al., 2011]. Suboptimal 
adherence to the immunosuppressive regimen causes a higher risk of late acute rejection and 
allograft loss [Constantiner and Cukor, 2011; Maclean et al., 2011]. A meta-analysis by [Butler et 
al., 2004] found that 36% (14%-65%) of graft losses were associated with prior non-adherence. 
This clearly demonstrates the clinical impact of non-adherence on patient outcomes highlighting 
this as an area of great unmet need with potential implications for health resource utilisation and 
cost.  
 
In this thesis data on the relative adherence rates between tacrolimus formulations and how this 
impacts graft survival and resulting economic consequences is evaluated. This is an area that has 
up to now never been explored and represents a new body of knowledge from both a clinical 
and economic perspective which has the potential to change clinical practice and reimbursement 
guidelines of immunosuppressive therapies. 
 
2.7 Chapter Sumary 
 
This chapter provided an overview of the prevalence and burden of ESRD and ESLD which 
consequently leads to transplantation. The value of immunosuppression therapy in post renal or 
liver transplantation was highlighted including improvements in HRQoL, patient and graft 
survival. Current treatment options, UK and international guidelines were discussed. Adherence 
and within-patient variability were identified as key unmet needs which have the potential to 
impact graft survival , increasing the risk of return to dialysis and or re-transplantation which is 
associated with significant clinical and economic burden on patients and healthcare services. In 
order to optimise long-term outcomes of patient and graft survival it is important to ensure the 
adoption of evidence based immunosuppressive therapy in clinical practice.  
 
The next chapter will focus on assessing the relative clinical effectiveness of immunosuppressive 
therapies in the treatment and management of adult renal or liver transplant recipients based on 
present author's published research 
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Chapter 3: Clinical Effectiveness of Immunosuppressive Therapy 
 
3.1  Introduction 
 
The previous chapter discusssed the burden of ESRD and ESLD, management of post renal and 
liver transplantation with immunosupressive therapies. This chapter will examine the clinical 
effectiveness of immunosuppressive therapy in adult renal and liver transplantation based on the 
author's published research with a view to recommending the most effective treatment strategy 
supported by evidence.  
 
The next section provides an overview of the studies conducted by the researcher Muduma et al., 
[2016] on the relative effectiveness of immunosuppresive therapy in renal and liver 
transplantation utilising systematic literature reviews, meta-analysis and indirect treatment 
comparison. Below a summary and critical commentary of the present author's two studies is 
presented starting with renal followed by liver clinical effectiveness. For both studies, the 
research question and study concept was developed by the present author who also had a leading 
project management role in addition to contributing to the study design, analysis and publication. 
 
3.2   Muduma G, Hart W, Patel S. Indirect treatment comparison of belatacept versus 
tacrolimus from a systematic review of immunosuppressive therapies for kidney transplant 
patients. Current Research and Medical Opinion. 2016; 30:1-8 (Publication 1). 
 
3.2.1  Description of the Study 
 
This research on indirect treatment comparison (ITC) of belatacept versus tacrolimus was 
developed in order to address the lack of clinical effectiveness data comparing tacrolimus 
formulations with belatacept in renal post-transplant immunosuppression. Immediate release 
tacrolimus (Prograf) has long been the mainstay therapy in renal transplant and is the 
recommended immunosuppressive treatment of choice within the current National Institute of 
Clinical Excellence [NICE, 2004] technology appraisal (TA) 85 which is currently under review. 
Since publication of NICE TA85 in 2004, newer therapies such as prolonged release tacrolimus 
(Advagraf) a newer formulation of tacrolimus and belatacept a selective co-stimulation were 
developed. However, there are no direct head to head trials comparing tacrolimus with 
belatacept. The aim of this study was to compare the clinical effectiveness of tacrolimus (Prograf 
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and Advagraf) and belatacept through a systematic review of immunosuppressive therapies in 
order to determine the most effective treatment strategy for renal transplant recipients using an 
indirect treatment comparison (ITC) approach.  
 
A systematic literature review was conducted comparing all formulations of tacrolimus, 
belatacept and ciclosporin in renal transplant recipients. Both more intense (MI) and less intense 
(LI) dosing regimens of belatacept were included in the study. The key endpoints captured in the 
review included glomerular filtration rate (GFR), acute rejection (AR), graft and patient survival.  
Searches of randomized controlled trials (RCTs) were carried out from EMBASE, Medline and 
Cochrane Library databases for publications covering period from 2002 to June 2013. It was 
assumed that the [NICE, 2004] technology appraisal (TA85) would have captured relevant data 
up to 2002. The relevant data prior to 2002 were combined with data from this systematic 
literature review for the meta-analysis. Utilising results from the meta-analysis an indirect 
treatment comparison was conducted between tacrolimus formulations and belatacept using 
ciclosporin as a common comparator. The Bucher et al., [1997] adjusted ITC model was used to 
calculate the relative risks of tacrolimus versus belatacept for graft failure, AR, patient mortality 
and mean difference of GFR. 
 
The literature search in line with the study protocol yielded a total of twenty one studies (21), 
nineteen (19) comparing tacrolimus formulations with ciclosporin and two (2) comparing 
belatacept MI and LI regimens with ciclosporin. Random effects modeling assuming that the 
true effect size varies among studies was selected over fixed effects model, taking into account 
both within and between studies heterogeneity [Borenstein et al., 2009]. 
  
The results of this ITC analysis showed no statistically significant difference in the GFR 
weighted mean difference between tacrolimus formulations and belatacept regimens. Similarly, 
there was no statistically significant difference between tacrolimus formulations and belatacept 
regimes for patient mortality and graft loss. However, the acute rejection rate was statistically 
significant lower with immediate and prolonged release tacrolimus relative to belatacept regimens 
0.22(0.13, 0.39) and 0.44(0.20, 0.99) respectively. 
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3.2.2 Evaluation of the Study 
 
The study results indicate that tacrolimus is associated with fewer acute rejections compared with 
belatacept and results are consistent with a manufacturer’s report from All Wales Medicines 
Strategy Group [AWMSG, 2012] and a recently published study [Goring et al., 2014]. The study 
also showed no statistically significant difference in GFR between tacrolimus and belatacept. 
However, a restricted analysis of belatacept versus tacrolimus using only one of the belatacept 
studies, Belatacept Evaluation of Nephroprotection and Efficacy as First line 
Immunosuppression Trial  (BENEFIT) showed a statistically significant GFR weighted mean 
difference in favour of belatacept. There is need for this endpoint to be explored further in a 
direct head to head study. This is imperative because GFR is a predictor of long term graft 
survival. 
 
A key strength of this publication is that it is the first ITC comparing tacrolimus formulations 
with both belatacept MI and LI dosing regimens to be published in a peer reviewed journal 
adding knowledge to this field. The findings can be used to inform decision making in clinical 
practice, as well as in health policy for example in updating clinical and reimbursement 
guidelines. Although this analysis focused on clinical outcomes, the study results provided part of 
the clinical data that was utilised in the renal cost utility analysis Publication 3, which included an 
economic evaluation comparing tacrolimus against a number of alternatives including belatacept 
in adult renal transplant recipients in the United Kingdom. 
 
The major strength of this study is that it utilised current and widely accepted methodology in 
ITC. The Bucher adjusted ITC method used in this study has been the foundation for indirect 
treatment comparisons in meta-analyses of RCTs [Wells et al., 2009]. More important the Bucher 
ITC method is widely accepted by drug reimbursement agencies such as the Australian 
Pharmaceutical Benefits Advisory Committee [PBAC, 2008], the UK National Institute of 
Clinical Excellence [NICE, 2008] and the Canadian Agency for Drug and Technologies in 
Health (CADTH) [Wells et al., 2009].  
 
Furthermore, the Bucher ITC method uses a statistical technique for making indirect 
comparisons of treatment effects that preserves the randomization of the originally assigned 
patient groups [Bucher et al., 1997]. This reduces confounding and bias of results. Unlike with a 
naıve ITC where comparisons of results across different trials break the original randomisation 
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and as such are subject to significant confounding and bias because of systematic differences 
between or among the trials being compared [Kim et al., 2014].  
 
However, there are shortcomings of this study which need to be acknowledged including 
limitations of the systematic review and meta-analysis in terms of variations in clinical and study 
design differences among the trials included in the analysis. These include varying uses of 
primary immunosuppression and concomitant medication, such as varied uses of the 
antiproliferative agents across trial arms, some using combinations of tacrolimus or ciclosporin 
with either mycophenolate mofetil or azathioprine. There were also varying administrative 
patterns for the drugs used in terms of dosages all of which could have a confounding impact on 
the outcomes affecting the accuracy of the results. 
 
Relatedly, variability in study outcomes was not investigated. Any heterogeneity in this study 
could have been assessed by an I2 test that describes the percentage of the variability that is due 
to heterogeneity rather than chance [Higgins and Green, 2008; Higgins et al., 2003]. Whilst the 
heterogeneity in this study was described and addressed by using random effects model the I2 
test was not perfomed. This could have provided more detail quantifying the magnitude of the 
heterogeneity. Depending on the extent of the heterogeneity a sensitivity analysis of the 
outcomes with substantial heterogeneity could have been done using fixed effects to assess the 
impact on the outcomes and robusness of results. In addition meta-regression analysis could 
have been performed to further investigate the heterogeneity. 
 
The analysis was further limited by the relatively short-term outcomes on which it was based, 
namely 12-month RCTs. Findings based on these relatively short-term outcomes may not be 
indicative of longer-term clinical outcomes. The 12-month duration of clinical trials included in 
this analysis on which the meta-analysis outcomes are based on can be argued to be inadequate 
given the chronic nature of immunosuppression therapy. The response seen in the RCT follow 
up period might not necessarily indicate how the patients might do over a long-term period in 
routine clinical practice as the disease evolves. Therefore, the external validity of the treatment 
outcomes based on limited treatment or follow up period such as in this study should be treated 
with caution. Basically, the veracity of this RCT based meta-analysis and ITC need to be 
complemented with routine clinical practice data covering long term follow up.  
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It is acknowledged that ITCs should be performed and can provide policy makers with useful 
information for clinical and economic decision-making. However, direct clinical evidence 
comparing two relevant treatments, through a randomized controlled trial with a long term 
follow up to establish the impact of the interventions as the disease evolves represents a strong 
evidence base. When RCTs are not available or cannot be conducted, researchers may resort to 
ITCs and interpret results carefully based on such analyses as in the case of this study. 
 
3.3 Conclusions 
 
This sudy presented the clinical effectiveness of tacrolimus formulations relative to belatacept. 
The results of this ITC suggests that tacrolimus is significantly superior to belatacept in terms of 
acute rejection outcomes but comparable for GFR, graft and patient survival. The key 
implication of this study is that belatacept is a newer drug, which has been suggested as a 
potential replacement for CNIs. This analysis fails to support the premise of replacing tacrolimus 
with belatacept in clinical practice. However, there is need for future research to include a 
properly designed clinical trial comparing tacrolimus versus belatacept directly with a long follow 
up period to determine the short and long-term outcomes of these therapies on renal transplant 
patients' including GFR, AR, patient and graft survival. Whilst this study focused on clinical 
effectiveness in renal transplant. The next section will examine a study on clinical effectiveness 
of immunosuppressive therapies in adult liver post-transplant recipients. 
 
3.4 Muduma G, Saunders R, Odeyemi I, Pollock RF. Systematic Review and Meta-Analysis of 
Tacrolimus versus Ciclosporin as Primary Immunosuppression after Liver Transplant. Public 
Library of Science (PLOS One) Journal, November 3, 2016 (Publication 2) 
 
3.4.1 Description of the Study 
 
Several meta-analyses comparing ciclosporin with tacrolimus have been conducted since the 
1994 publication of the tacrolimus registration trials, but most captured data from randomized 
controlled trials (RCTs) predating recent improvements in waiting list prioritization, induction 
protocols and concomitant medications. In the interest of evidence-based medicine, the 
established understanding from these meta-analyses should be periodically reviewed to ensure 
that it remains grounded in fact, particularly in cases where other complementary aspects of 
treatment are evolving alongside the primary therapies comprising the standard of care which is 
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the case in liver transplantation. This study was designed to address the need for an up-to-date 
meta-analysis of RCTs of ciclosporin and tacrolimus. This meta-analysis was the first analysis of 
post-transplant immunosuppression in liver transplant recipients conducted based exclusively on 
RCTs published since 2000, representing the most recent available data and therefore reflecting 
current clinical practice.  
 
A systematic literature review was conducted based on searches from PubMed, Cochrane Library 
and EMBASE databases covering publications between January 2000 and August 6, 2014. The 
search strategy was designed to identify RCTs comparing all formulations of tacrolimus with 
ciclosporin used as primary immunosuppression therapy in adult patients receiving their first 
liver transplant.  
 
The literature searches yielded forty nine (49) studies which were reviewed and identified eleven 
(11) relevant RCTs for inclusion in the meta-analysis. No studies were identified comparing 
prolonged release tacrolimus with ciclosporin. Only one RCT was identified comparing 
immediate release with prolonged release tacrolimus. The key study endpoints extracted for 
analysis included; acute rejection (AR), patient mortality, graft loss, new onset of diabetes 
(NODAT) and hypertension at 12 months. 
  
Based on the extracted endpoints data a meta-analysis was undertaken to calculate the relative 
treatment effects of interventions using a random effects model for the base case analysis. In 
order to assess the robustness of the results, a number of sensitivity analyses were undertaken in 
which the outcomes were reported as odds ratios and risk differences. Fixed effects model was 
used instead of the random effects model adopted in the base case analysis.  
 
This study results are based on endpoints which had sufficient data for analysis that is AR, 
hypertension, graft loss, mortality and NODAT. Relative to ciclosporin, tacrolimus was 
associated with significantly improved outcomes in terms of patient mortality (risk ratio [RR] 
with ciclosporin of 1.26; 95% confidence interval [95%CI] 1.01-1.58). Tacrolimus was superior 
to ciclosporin in terms of hypertension (RR with ciclosporin 1.26; 95%CI 1.07-1.47), but inferior 
in terms of NODAT (RR with ciclosporin 0.60; 95%CI 0.47-0.77). There were no significant 
differences between ciclosporin and tacrolimus in terms of graft loss or AR. 
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3.4.2 Evaluation of the Study 
 
This systematic literature review and meta-analysis showed that tacrolimus is significantly more 
effective than ciclosporin in terms of patient survival and hypertension. Conversely, patients on 
ciclosporin had a lower risk of developing NODAT than those on tacrolimus. No other 
investigated outcomes significantly differed between ciclosporin and tacrolimus. However, 
analyses of patient survival and graft loss in Hepatitis C Virus (HCV) subgroups were opposite 
to those in the whole population.  
 
The finding that patient mortality was significantly reduced in patients using tacrolimus relative 
to ciclosporin is consistent with previous meta-analyses. For instance, in 2006, Haddad and 
colleagues reported a relative risk of mortality of 0.85 (95% CI 0.73, 0.99) with tacrolimus 
relative to ciclosporin [Haddad et al., 2006]. Similarly, Haddad et al., [2006] reported a 
significantly higher risk of NODAT with tacrolimus relative to ciclosporin with a risk ratio of 
1.27, compared to the RR of 0.59 with ciclosporin relative to tacrolimus in the present study. 
However, the meta-analysis by Haddad et al., [2006] also reported an 18% reduction in the risk of 
acute rejection with tacrolimus versus ciclosporin, an endpoint around which this study identified 
no significant difference. This is probably due to the fact that with newer CNI formulations 
there has been a drastic reduction in patients experiencing acute rejections. Given this analysis 
focused on recent data these results might just be explaining what is happening in current clinical 
practice. 
 
Outcomes in the HCV subgroup analysis of graft loss were also in line with a meta-analysis by 
Liu et al., [2014]. Liu and colleagues reported a graft loss risk ratio of 1.05 (95% CI: 0.83–1.33) 
with tacrolimus relative to ciclosporin, which matches the present study directionally the risk 
ratio for graft loss in the HCV subgroup was 0.52 (95% CI 0.28, 0.98; p = 0.04) with ciclosporin 
relative to tacrolimus. This difference in outcomes in the HCV sub group which is opposite to 
the whole population is believed to be due to the way the CNIs work. While both tacrolimus and 
ciclosporin are CNI inhibitors, the mechanism of inhibition is distinct, with ciclosporin blocking 
efficient HCV replication in vitro by binding to regulators of the HCV ribonucleic acid (RNA) 
polymerase, independently of its immunosuppressive effect. Tacrolimus, conversely, binds to 
FK506 binding proteins, which are not required for HCV replication [Watashi et al., 2005]. 
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While hypertension was not investigated in the meta-analysis by Haddad et al., [2006], the present 
study showed that tacrolimus would be expected to result in reduced incidence of hypertension 
relative to ciclosporin, a finding that is in line with the results of a meta-analysis comparing 
tacrolimus with ciclosporin in recipients of other solid organ grafts [Penninga et al., 2010]. 
However, it should be noted that the results of the hypertension analysis from the present study 
was informed by a small number of studies that is four of the eleven included in the review. 
Therefore, further research is needed to validate these results. 
 
Similar, to previous study Publication 1, this analysis main strength lies in its use of widely 
accepted evidence synthesis methodology. In addition, a specific strength of this publication is 
that the study analysis and reporting was done in line with the Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses (PRISMA) checklist. Furthermore, the Cochrane 
collaborations risk of bias tool was used to assess risk of bias including selection and reporting 
bias hence the study was conducted following good research practice. 
 
Another key strength of this study is that unlike the previous study Publication 1, in this analysis 
study heterogeneity was ascertained by the I2 statistic for each outcome. Furthermore, 
comprehensive sensitivity analyses were performed to assess the robustness of the results. For 
example the high heterogeneity in the graft loss analysis (I2 of 53%) indicated a high variability. 
This was addressed by the use of random effects analysis model for the base case and fixed 
effects as a sensitivity analysis. The graft loss analysis was affected by the switch to a fixed effects 
analysis, with a fixed effects model yielding a RR of 1.02 (95% CI: 0.67–1.56), reduced from a 
RR of 1.20 (95% CI: 0.57–2.53) in the random effects analysis. The difference between random 
and fixed effects model outcomes may suggest that the random effects estimate, while likely 
more appropriate than a fixed effects model given the heterogeneity across studies, is not 
reflective of the true difference between treatments. Changes to the model and the reported 
outcome measure made no difference to the AR analysis, which remained non-significant across 
all analyses. 
 
Finally, the analysis focused on RCTs published since 2000. This ensured that the data was more 
reflective of the present immunosuppression era and therefore representing current clinical 
practice. In addition, the analysis also validated previous studies and meta-analyses to ensure 
evidence is still relevant.   
 
  
32 
 
However, there are some limitations associated with the study which need to be acknowledged 
including publication bias and heterogeneity. A potential source of publication bias, in this 
analysis is the omission of studies that have not been published or have only been published in 
abstract form. Nevertheless, this was mitigated by the study protocol that only included fully 
published studies because of peer review rigour they would have undergone. 
 
This study also did not compare prolonged release tacrolimus formulation with Ciclosporin. 
Only one RCT of once-daily tacrolimus was identified in the literature. The study, published by 
Trunečka et al., [2010], compared twice-daily tacrolimus with once-daily tacrolimus in liver 
transplant recipients. The study was excluded from the meta-analysis as there was no comparison 
with ciclosporin and an indirect treatment comparison was not performed on the grounds that 
only this single non-inferiority study was identified. On reflection this analysis could have 
benefited from an ITC of prolonged release tacrolimus and ciclosporin based on this one 
identified RCT to get an indication of direction of the outcomes at the same time acknowledging 
the limitations of basing such analysis on one trial. 
 
Finally, similar to previous study Publication 1, (section 3.2.2) these study outcomes were based 
on RCT data which has a stringent inclusion and exclusion criteria. The results of this meta-
analysis are therefore, applicable to specific group of patients in line with the RCT study 
protocols. These strict eligibility criteria can effectively limit the generalisability of the results by 
limiting the group of patients which the results could be applied on in routine clinical practice. 
Consequently, this could potentially limit the patient population eligible for reimbursement in 
some healthcare systems based on these RCT data. 
 
3.5 Conclusion 
 
This study showed that, despite numerous changes in other aspects of routine care for liver 
transplant recipients, tacrolimus remains superior to ciclosporin in liver transplant recipients with 
respect to mortality and hypertension. While ciclosporin resulted in significantly lower incidence 
of NODAT than tacrolimus. Further research is required to establish the efficacy of prolonged-
release tacrolimus relative to immediate-release tacrolimus and ciclosporin in liver transplant 
recipients.  
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3.6 Chapter  Summary 
 
This chapter examined the relative effectiveness of immunosuppressive therapy used in adult 
renal and liver transplant. The two articles included in this chapter described an update on 
immunosuppressive clinical effectiveness evidence in adult post renal and liver transplantation 
which added new knowledge to the field. The studies were developed to address a gap in 
literature and the research was conducted using well established evidence synthesis 
methodologies. Both strengths and limitations of the research were highlighted. The findings of 
the research provide further evidence supporting the use of tacrolimus as the cornerstone of 
immunosuppressive therapy in both liver and kidney transplant recipients. However, further 
research is needed to establish the long-term effectiveness of immunosuppression therapy in 
post renal and liver transplantation in routine clinical practice. Whilst it is important to establish 
the clinical effectiveness of therapies. In mordern day resource constrained healthcare systems it 
is even more imperative to demonstrate the economic consequences of the different therapies 
used in clinical practice.  
 
The next chapter will look at the cost-effectiveness of immusuppressive therapy in renal and 
liver transplant. 
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Chapter 4: Cost effectiveness analysis of immunosuppressive therapy 
 
4.1 Introduction 
 
The thesis so far has discussed the burden of ESRD and ESLD and the clinical effectiveness of 
immunosuppressive therapy in this area. This chapter, will focus on how the findings from the 
clinical effectiveness and other relevant data sources were used to develop cost-effectiveness 
analyses of immunosuppressive therapy in adult renal and liver transplant recipients from a UK, 
NHS payer perspective. 
 
This chapter will examine the health economic evaluation of immunosuppressive therapy in 
adult renal and liver transplant recipients based on author's research with a view to recommend 
the most cost effective treatment strategy. Three publications are presented covering three 
economic evaluation models; a renal transplant cost utility analysis based in part on clinical data 
from the indirect treatment comparson (ITC) publication 1 discussed in chapter 3, cost utility 
analysis in post liver transplantation immunosuppression based on outputs from a network 
meta-analysis (NMA), and a cost-effectiveness analysis in post liver transplant 
immunosuppression based on routine clinical practice data.  
 
4.2  Muduma G, Shaw J, Hart W, Odeyemi A, Odeyemi I.  Cost utility analysis of 
immunosuppressive regimens in adult renal transplant recipients in England and Wales. Patient 
Preference and Adherence. 2014; 8:1537-46. (Publication 3) 
 
4.2.1 Description of the Study 
  
Tacrolimus is the Standard of Care (SoC) in renal post-transplant immunosuppression in the 
United Kingdom (UK) and is currently recommended by National Institute of Health and 
Clinical Excellence (NICE) guidelines technology assessment (TA) 85 [NICE, 2004]. Prior to 
2013, no health economic analysis had been conducted comparing immediate-release tacrolimus 
to newer immunosuppressive agents introduced on the market post NICE TA 85 [NICE, 2004] 
review.  
 
The renal cost utility analysis was developed to address this lack of economic evaluations of renal 
post-transplant immunosuppression regimens in the UK since the publication of an economic 
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evaluation by [Woodroffe et al., 2005] based on the NICE review. The aim of this study was to 
carry out a cost utility analysis of immunosuppression, including more recent agents such as a 
once daily prolonged-release formulation of tacrolimus (Advagraf) and Belatacept a first in-class 
co-stimulation blocker, relative to a twice-daily immediate-release formulation of tacrolimus 
(Prograf) from a UK National Health Service (NHS) payer perspective.  
 
A Markov model was constructed to represent the patient flow following successful kidney 
transplantation. The model comprised six health states: onset of biopsy confirmed acute 
rejection (BCAR), functioning graft with or without a biopsy-confirmed acute rejection, non-
functioning graft (dialysis), re-transplantation, and death. Patients could be in only one of the 
finite health states at any given time point in the simulation. The health states were developed in 
consultation with clinicians and validated by Key Opinion Leaders (KOLs) at an advisory board. 
The model used a 1-year cycle length and was designed to support time horizons of between 5 
and 25 years. The model used underlying rates of graft failure from the National Health Service 
Blood and Transplant (NHSBT). Data on clinical effectiveness were derived from a systematic 
literature review. The model captured the effects of patient adherence to immunosuppressant 
therapy on graft survival using relative risk of graft survival based on published data on odds of 
graft failure and adherence to once and twice daily tacrolimus from [Butler et al., 2004, Kuypers et 
al., 2013]. Health related quality of life utility values for functioning renal transplant, 
hemodialysis, and peritoneal dialysis were also derived from the literature [Lee et al., 2005]. 
Comparator drugs in the analysis included Advagraf, Prograf, belatacept, sirolimus and 
ciclosporin. In the base case, the time horizon was 25 years, one way and probabilistic sensitivity 
analyses were conducted. One way sensitivity analyses indicated that Incremental Cost 
Effectiveness Ratios (ICERs) were affected by the time horizon and effect of adherence. 
However, overall the results were not sensitive to changes from other variables such as discount 
rate, costs and utilities associated with dialysis suggesting the model is robust. 
 
The results showed that in the base case immediate release tacrolimus was cost-effective when 
compared with ciclosporin and belatacept and was more effective than sirolimus, but would not 
be considered cost effective against sirolimus. Prolonged release tacrolimus dominated 
immediate release tacrolimus. 
 
Advisory Boards were utlised in this study and in publications 4 and 7 as a methodological tool 
to elicit information and validate data to ensure that economic modelling assumptions were in 
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line with clinical practice. The Advisory Boards were composed of multi-disciplinary experts in 
the field of transplantation including Physicians, Nurses, Payers/Commissioners and Pharmacist. 
The advisory boards provided expert opinions which were taken into account in order to ensure 
that the outputs from the economic analysis were aligned with what happens in the clinical 
environment. 
 
4.2.2 Evaluation of the study 
 
The study showed that Advagraf is the most cost effective option compared to Prograf the 
current SoC. This result was driven to a large extent by the high adherence rates of Advagraf 
relative to Prograf which impacts graft survival rates and consequent costs associated with 
treating graft loss that is dialysis and or re-transplantation. Advagraf and Prograf were seen to be 
more effective and less costly relative to belatacept a new agent which was developed with the 
intention to replace CNIs. The cost and significantly higher acute rejection rate associated with 
belatacept compared with CNIs in the first 3 months of therapy as detailed in a recent report of 
the All Wales Medicines Strategy Group could act as a barrier to the wider use of belatacept in 
England and Wales [AWMSG, 2014]. 
 
In terms of contribution to knowledge this study represented the first cost-utility analysis to be 
published on post-renal transplant immunosuppression that captured the effects of patient 
adherence specifically to tacrolimus formulations. There is evidence suggesting a link between 
graft survival and adherence to immunosuppressive therapy in renal transplant as discussed in 
Chapter 2 (section 2.6.2). However, up to now the potential economic impact of adherence on 
graft survival had never been assessed in health economic models for post renal transplantation. 
 
The key strength of this study is therefore its ability to model adherence data to graft survival 
and resulting economic consequences. This modeling approach is innovative in post renal 
transplant area and could be used as a basis for further adherence data based economic models 
in post liver transplantation and other therapeutic areas.  
 
The second strength of this study is that the analysis compared the current SoC immediate 
release tacrolimus with all relevant interventions for primary immunosuppression in post renal 
transplant. In addition to established products the analysis included new products and 
formulations in the model reflecting current clinical practice. Furthermore, the model represents 
a significant update to the health economic evidence base in renal post-transplant 
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immunosuppression in the UK since the publication by [Woodroffe et al., 2005]. Therefore, this 
study contributed to knowledge in this area which could help payers make informed decisions 
for their reimbursement guidelines on post renal transplant immunosuppression. 
 
Finally, the health states and economic model were validated by a panel of experts at an advisory 
board which was multidisciplinary including health economics, renal transplant physicians and 
healthcare professionals. Therefore, another key strength of this study is that the economic 
model was developed following good practice incorporating what KOLs would expect to be in a 
credible model. Consulting with subject experts assured that the model addressed the research 
question and disease processes adequately. 
 
However, like most studies there are limitations which need to be acknowledged. The first  
limitation of this study which is inherent in most health economic analyses is that of multiple 
data sources used to derive the model inputs. A number of data sources were used in the model, 
underlying graft failure rates from NHSBT, mortality data from the Office for National Statistics, 
adherence data from [Kuypers et al., 2013], graft failure odds from [Butler et al., 2004], dosing 
data from [Silva et al., 2007],  and drug prices from the British National Formulary. Whilst the 
use of heterogeneous data sources is common practice in modeling it nevertheless needs to be 
highlighted as a potential limitation since the different data sources have varying degrees of 
quality which could affect the accuracy of the results. To mitigate the impact of heterogeneity of 
the data sources one way and probabilistic sensitivity analyses were conducted. The analyses 
suggest that the results are robust. However, the ICERs were impacted by changes in time 
horizon and effect of adherence.   
 
The second limitation was the lack of patient adherence data for belatacept, sirolimus and 
ciclosporin. Whilst this study represented the first time adherence data was used in a health 
economic evaluation of immunosuppressants the data was only used for Advagraf and Prograf 
arms. It is recommended that future studies capture long-term adherence data for all the 
competing interventions and model them accordingly. This is would result in a more 
comprehensive comparison of all relevant interventions using the same approach for 
effectiveness data. This is important since in renal transplantation adherence with 
immunosuppresants is linked to improved graft survival which impacts patient HRQoL, return 
to dialysis and or re-transplantation and the resulting costs. 
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Finally, the study adopted a payer perspective which meant that the analysis did not include 
indirect costs such as productivity which might affect a proportion of this patient population as 
renal transplantation is associated with significant loss of productivity. In this regard the analysis 
could be considered to be an underestimation of the total burden of renal transplantation on the 
UK society. 
 
4.2.3 Conclusion 
 
Prograf appears to maintain its status as the SoC for the immunosuppression of renal transplant 
recipients against relevant comparators in the UK. National recommendations should consider 
Advagraf as a viable alternative to Prograf as the SoC due to the improvement in graft survival 
attributable to the improvement in adherence observed in patients taking the once daily 
formulation. In addition based on this analysis Advagraf was the only drug found to be more 
effective and less costly relative to Prograf the current SoC. This could have implications for the 
UK, national reimbursement guidelines which are currently under review with NICE. The next 
paper will review the cost utility analysis in post liver transplantation based on NMA data. 
 
4.3.1  Muduma G, Odeyemi I, Pollock RF. A Cost-Utility Analysis of Prolonged-Release 
Tacrolimus Relative to Immediate-Release Tacrolimus and Ciclosporin in Liver Transplant 
Recipients in the UK. Journal of Medical Economics 2016; 19(10): 995-1002.  (Publication 
4) 
 
4.3.2  Description of the study 
 
This cost utility analysis of prolonged-release tacrolimus relative to immediate-release tacrolimus 
and ciclosporin was designed to address the lack of economic studies of immunosuppressive 
therapies in post liver transplantation in the UK. Prior to this study no health economic analysis 
had been conducted ever comparing immunosuppressive agents in post liver transplantation in 
the UK. The present author conceived the research question in order to address this gap in 
literature. In addition to the study design and analysis the present author led the project 
management of the research and publication. Calcineurin inhibitors (CNIs) represent the 
cornerstone of immunosuppressive therapy after liver transplantation. This indicates that CNIs 
are clinically effective. However, it is important to have estimates of the cost effectiveness of 
immunosuppressive therapies, in order to ensure that limited healthcare resources are being 
allocated efficiently into a product(s) that optimises HRQoL, patient and graft survival. This 
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study evaluated the cost utility of prolonged-release tacrolimus relative to ciclosporin or 
immediate-release tacrolimus in liver transplant recipients from a UK, NHS payer perspective. 
 
A three health states Markov model was developed to evaluate the cost-utility of 
immunosuppressive regimens in liver transplant recipients, capturing costs associated with 
immunosuppression, re-transplantation, acute rejection (AR), and cytomegalovirus infection. The 
three health states were alive with first transplant, alive after retransplantation, and dead. No 
states were included to capture recurrence of conditions for which liver transplant was indicated, 
such as hepatocellular carcinoma (HCC) and hepatitis C virus (HCV). Mortality, graft loss, and 
AR odds ratios were derived from a network meta-analysis (NMA). Transitions between states 
were based on underlying rates of mortality from the NHSBT, while rates of re-transplantation 
were derived from [Marudanayagam et al., 2010]. Differential rates were then calculated based on 
the odds ratios reported in the NMA. The model also captured rates of acute rejection in year 1 
of the analysis and supported time horizons of up to 25 years, extrapolating from the 10-year 
NHSBT mortality data using a rational model fit to the Kaplan-Meier curves. Costs were taken 
from the British National Formulary and the NHS National Tariff and expressed in 2016 pounds 
sterling. Future costs and effects were discounted at 3.5% annually in line with NICE guidelines 
on discounting [NICE, 2008]. All simulations were conducted using probabilistic sensitivity 
analysis in which key model parameters were sampled to capture the uncertainty around model 
inputs. Additionally, a series of one-way sensitivity analyses were conducted. The base case 
analysis was performed over a 25-year time horizon. This approach was taken to capture the full 
effectiveness differences between the respective treatments and for consistency with another 
recent cost-utility analysis of immunosuppressive regimens after solid organ transplantation 
[Muduma et al., 2014].  
 
The base case analysis, showed prolonged release tacrolimus resulted in increased life expectancy 
and quality-adjusted life expectancy (QALE) relative to immediate release tacrolimus and 
ciclosporin. Relative to ciclosporin, QALE increased by 1.17 quality adjusted life years (QALYs) 
with prolonged release tacrolimus while costs increased by GBP £4645, yielding an incremental 
cost-effectiveness ratio (ICER) of £3962 per QALY gained. Relative to immediate release 
tacrolimus, QALE increased by 0.78 QALYs and costs by £1474, resulting in an ICER of £1889 
per QALY gained. Deterministic sensitivity analysis showed the model to be most sensitive to 
dosing assumptions of tacrolimus. 
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4.3.3 Evaluation of the study 
 
The study analysis suggests PR tacrolimus is highly cost effective and should be considered as 
the first line treatment in post liver transplant immunosuppression. Similar to previous 
publication 3, a key strength of this study is the wide consultation with clinical experts that 
informed the model structure and choice of health states. This ensured that the model adequately 
addressed the research question.  
 
Also a critical strength of this study is the fact that the clinical outcomes data driving the model 
were derived from a NMA which combined data from RCTs and large observational studies 
using a Bayesian confounder controlled hierarchical model. This data set is more robust than 
RCT only data since it brings in a component of routine clinical practice into the analysis. An 
approach and data source which is likely to be well received by payers [Stegenga et al., 2017] 
 
Another key strength of the study is the targeted nature of the model which focused on patient 
population with non-recurrent conditions for which liver transplant is indicated. This allowed for 
a more transparent evaluation of the impact of immunosuppression which would be lost if for 
instance patients with recurrent HCV and HCC were to be included in the analysis. In addition 
the model structure and assumptions were validated by clinical experts. 
 
However, the study has limitations that should be acknowledged when interpreting the findings. 
Similar to the previous paper publication 3 (section 4.2.2), the main limitations of this analysis 
was the adoption of a payer perspective and the use of heterogeneous data sources for the 
clinical efficacy parameters, health utilities, body weight and the dosing assumptions. As in 
publication 3, the impact of the heterogeneous data sources was mitigated to a great extent 
because all simulations of ICERs were conducted using probabilistic sensitivity analysis in which 
key model parameters were sampled to capture the uncertainty around model inputs. 
Nevertheless, the model was sensitive to the long term dosing assumption based on RCT data 
which was then extrapolated for the 25 year time horizon of the analysis. Until long-term data on 
immunosuppressive dosing become available, long-term dose modeling will continue to be a 
challenge in health economic analyses of immunosuppressive products. This indicates the need 
for collection of longitudinal dosing data to address the uncertainty associated with this variable.  
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This study was designed specifically for the purposes of modeling cost-utility in non-recurrent 
indications for liver transplant which is strength in terms of transparent modeling. However, 
given that the highest indication for liver transplant is Hepatitis C Virus (HCV). The results of 
this analysis are unlikely to be applicable to patients with HCV. Nonetheless, limitations around 
the exclusion of HCV should be alleviated by the approval of the second generation direct-acting 
antivirals (DAAs) with HCV cure rates up to 100% [Afdhal et al., 2014]. This should mean the 
number of people indicated for liver transplantation due to HCV should go down and any 
recurrence of HCV after liver transplantation could be successfully treated. Therefore, the 
current model exclusion of HCV population might not be a huge limitation as HCV treatments 
evolve in clinical practice. 
 
Finally, the cost estimate for liver re-transplantation was based on costs from a single center 
study. Whilst the cost of retransplantation is being derived from a single data source. It has to be 
highlighted that the single centre study as good as it might be it might not reflect clinical practice 
of other centres. The specific center protocols and practices, may have affected the cost 
estimates presented, and the final cost estimate may not be applicable to other centers affecting 
the generalisability of this study. Therefore, there is need to gather re-transplantation cost data 
from multiple centers to take into account the potential clinical diversity and hence varying costs. 
This data can be used to update the analysis assessing the impact on the results relevant to 
clinical practice and reimbursement requirements. 
 
4.3.4 Conclusions 
 
Based on this UK, specific analysis of the projected cost-utility of PR tacrolimus relative to IR 
tacrolimus and ciclosporin, PR tacrolimus was cost effective, improving life expectancy and 
QALE relative to both IR tacrolimus and ciclosporin, yielding ICERs below £20 000 per QALY 
gained. The main limitations of the study were the cost estimate for liver re-transplantation and 
lack of long-term routine clinical practice data on immunosuppression dosing.  
 
Whilst this publication was based on data from a NMA the next study will present the first 
within trial liver cost effectiveness analysis based on routine clinical practice data which 
represents a significant advance in immunosuppression therapy economic modeling. 
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4.4.1  Muduma G, Odeyemi I, Pollok RF. Evaluating The Cost-Effectiveness of Prolonged-
Release Tacrolimus Relative To Immediate-Release Tacrolimus in Liver Transplant Patients 
Based on Data From Routine Clinical Practice. Drugs - Real World Outcomes Journal. 2016;3:61-68 
(Publication 5) 
4.4.2 Description of the study 
 
 Data from RCTs alone do not always provide the information that HTAs and reimbursement 
agencies require to make their decisions on adoption of a technology. As a consequence, 
increasingly reimbursement and market access decisions require evidence of relative effectiveness 
of an intervention compared to the SoC when used in routine clinical practice [Stegenga et al., 
2017]. This economic analysis is based on clinical outcomes from routine clinical practice. The 
present author conceived this study to address the lack of economic models in post liver 
transplant immunosuppression in the UK, based on routine clinical practice data. Immediate 
release tacrolimus is currently the cornerstone of post-transplant immunosuppression in liver 
transplant recipients. However, a recent propensity-score matched analysis of data from the 
European Liver Transplant Registry (ELTR) has demonstrated a significant improvement in 
graft survival in patients on prolonged-release, once-daily versus immediate-release, twice-daily 
tacrolimus [Adam et al., 2015]. These emerging data appear to corroborate the findings of 
previous studies that have demonstrated improved adherence with reduced pill burden, and 
improved graft outcomes with improved adherence [Eberlin et al., 2013; Kuypers et al., 2013; 
Florman et al., 2005]. Given the substantial effect that these findings may have on incidence of 
graft loss in liver transplant recipients. The objective of this study was to evaluate the cost-
effectiveness of prolonged-release tacrolimus (PRT) versus immediate-release tacrolimus (IRT), 
the current SoC in liver post-transplant immunosuppression. The analysis was conducted using 
routine clinical practice data from the ELTR focusing on both the monetary and epidemiological 
implications of using PRT relative to IRT. As with the previous study in addition to contributing 
to the study design and data analysis the present author led the project management of this 
research. 
 
A cost effectiveness model was developed in Microsoft Excel. The model was a Kaplan-Meier 
based analysis of patient and graft survival data from the ELTR, capturing costs of primary 
immunosuppressive medications and re-transplantation over the three-year time horizon of the 
ELTR data analysis.  
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Over a 3 year time horizon, the numbers needed to treat with PRT relative to IRT were 14 to 
avoid one graft loss and 18 to avoid one death. The base case demonstrated that PR tacrolimus 
was less costly and more effective than IR tacrolimus meaning IR tacrolimus was dominated. 
However, the model was sensitive to dosing assumptions, with incremental cost estimates 
varying between a saving of GBP 1,642 (standard deviation GBP 885) per patient, assuming the 
same dosing of PRT and IRT (per kilogram bodyweight) and an increase of GBP 1,350 (GBP 
964) using RCT dose data. 
 
4.4.3 Evaluation of the study 
 
The study showed that, based on a recent retrospective analysis of routine clinical practice data 
from the ELTR, PR tacrolimus would be expected to be associated with higher gains in life 
expectancy and graft survival relative to IR tacrolimus. In addition PR tacrolimus would reduce 
costs incurred by the healthcare payer.  
 
This study had significant contributions in a number of areas. The study represented the first 
within-trial analysis of cost effectiveness in liver transplant recipients and the first attempt to 
estimate the pharmacy and re-transplantation costs based on the findings of a long-term study in 
routine clinical practice. Furthermore, this cost-effectiveness analysis represented the first health 
economic model of post liver transplant immunosuppression to report outcomes in natural units 
such as cost per graft month gained and numbers needed to treat to avoid graft failure. While the 
cost analysis presented is UK specific, the epidemiological results derived from the ELTR data 
are likely to be applicable to many countries.  
 
In addition to the contribution to knowledge this study's key strength is that the economic 
analysis was based on clinical outcomes data derived from a retrospective analysis of routine 
clinical practice data without the need to extrapolate the data beyond the duration of the study. 
This had the benefit of reducing the uncertainty associated with the extrapolation of data beyond 
that observed in the study. Furthermore, the clinical outcomes used in the analysis were derived 
from a single source without the need to model surrogate markers to hard outcomes of graft and 
patient survival. 
 
Another key strength of this publication is the new dimension it brought to the cost 
effectiveness analysis of immunosuppression in post liver transplantation. Whilst the previous 
cost utility analysis studies (Publications 3 and 4) were modelled on clinical data from ITC and 
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NMA. This study used the ELTR real world data to model the cost effectiveness of 
immunosuppression in post liver transplant. Since key clinical outcomes of patient and graft 
survival used in the model were derived from a real world experience which reflects what 
happens in routine clinical practice. It can therefore, be argued that this study presents clinical 
and economic effectiveness of tacrolimus formulations in post liver transplantation recipients 
based on real world evidence. This is in line with payers' expectations in terms of using RWE in 
economic evaluations [Stegenga et al., 2017]. This study is a significant advance in modelling of 
post liver transplant immunosuppression which could be used as a template in post renal 
transplantation where so far no economic model has been developed based on real world data.  
 
As with any cost effectiveness analysis, this study has a number of limitations that should be 
acknowledged. Similar to the previous study, publication 4 (section 4.3.3), the most significant 
limitations of this analysis include the use of a single center costs to inform the re-transplantation 
costs, payer perspective and the lack of longitudinal immunosuppression dosing. In fact dosing 
data were not recorded in the ELTR and as such did not form part of the retrospective analysis 
by [Adam et al., 2015] that underpinned the clinical aspects of this analysis. A series of 
probabilistic and one way sensitivity analyses were employed to address these concerns.  
 
Finally, this study provides a great platform from where routine clinical practice data can be 
further extended to collect a number of variables not currently captured in the ELTR data such 
as long term dosing. This is needed in economic modelling of immunosuppression therapy since 
current models are sensitive to dosing assumptions based on short-term RCT data. 
 
4.4.4  Conclusion 
 
Based on this analysis, PR tacrolimus is superior in graft and patient survival relative to IR 
tacrolimus. Moreover, PR tacrolimus was less costly and more effective than IR tacrolimus. This 
provides a strong rationale for the adoption of PR tacrolimus over IR tacrolimus in adult liver 
transplant recipients in the UK healthcare system. 
 
4.6  Chapter Summary 
 
Three articles included in this chapter each summarised and critiqued the approach taken in the 
development of cost utility and effectiveness analyses in renal and liver post–transplant 
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immunosuppression. The studies provided new knowledge and significant update on economic 
analyses of post liver and renal transplant immunosuppression therapy. The analyses confirmed 
that tacrolimus maintains its position as the cornerstone of post-transplant immunosuppression 
therapy. The prolonged-release tacrolimus (Advagraf) appears to be the most cost effective 
option in the UK setting. The routine clinical practice based cost effectiveness analysis provided 
a template of how real world data could be used in economic modeling in immunosuppression 
therapy. However, further work is required to address the heterogeneity of data sources used in 
the economic modelling in particular the linking of adherence rates with graft survival from 
different trials with different study design and patient populations. In addition, collection of 
longitudinal dosing data would go a long way in addressing the uncertainty surrounding this key 
variable in long term economic modeling of immunosuppression therapy in post-transplantation. 
These analyses provide much needed evidence in this area to inform clinical and reimbursement 
guidelines in the UK and after adaptation in other countries.  
 
Whilst CEAs help with priority setting there is also need to assess affordability and sustainability 
of funding at a local, regional and national level. The next chapter will focus on the budget 
impact analysis of tacrolimus formulations in post-renal transplant immunosuppression and how 
this might influence local decisions on product adoption. 
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Chapter 5: Budget impact analysis of immunosuppression therapy 
  
5.1  Introduction 
 
The previous chapter examined the cost-effectiveness of post-transplant immunosuppression. 
Whilst cost effectiveness and cost utility analyses help healthcare decision makers in assigning 
priority to efficient interventions. Budget Impact Analysis (BIA) is useful in assessing 
affordability of interventions and hence sustainability of their funding. Therefore, BIA is key to 
product adoption and patient access to medicines [Orlewska and Gula´csi, 2009]. This chapter 
will focus on BIA of renal post-transplant immunosuppression specifically tacrolimus 
formulations.  
 
Prior to 2013, no tacrolimus formulations BIAs had been conducted in renal transplant and 
hence a significant gap in literature. The within-patient variability (Publication 6) and patient 
adherence (Publication 7) budget impact analyses were developed to address this gap. Similarly, 
the antibody-mediated rejection (AbMR) based budget impact analysis (Publication 8) was 
subsequently developed to conduct a health economic analysis of data from a retrospective study 
showing an association between non-adherence to immunosuppression, AbMR and graft loss. 
Similar to the previous papers in addition to taking a lead role in the project management of the 
studies the present author also contributed to the research design and analysis of the three 
articles to be critically evaluated in this chapter.  
 
5.2 Muduma G , Odeyemi I , Pollock R .A UK Analysis of the cost of switching Renal 
Transplant Patients from an Immediate-release to a Prolonged-release formulation of tacrolimus 
Based on differences in Trough Concentration Variability. Journal of Medical 
Economics 2014; 17(7): 520-6 (Publication 6) 
 
5.2.1  Description of the Study 
 
Randomised controlled trials have shown that a once-daily prolonged-release (PR) tacrolimus 
formulation (Advagraf) is non-inferior to a twice-daily immediate-release (IR) tacrolimus 
formulation (Prograf) in terms of biopsy-confirmed acute rejection, graft failure and mortality in 
renal transplant recipients [European FK506, 1994; US FK506, 1994]. While studies have 
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demonstrated that tacrolimus has a well-characterised efficacy and safety profile in patients at 
risk of post-transplantation graft rejection, doses that result in tacrolimus exposure outside of the 
therapeutic range can result in an increased risk of rejection (with low tacrolimus concentrations) 
or toxicity (with high tacrolimus concentrations). However, relative to IR tacrolimus, PR 
tacrolimus exhibits reduced tacrolimus trough concentration variability, which has been 
associated with reduced graft failure. Based on these data, this study evaluated the cost of 
switching UK renal transplant patients from IR tacrolimus to PR tacrolimus. 
 
An Excel based cohort model was developed to model rates of renal graft failure in patients 
prescribed Prograf versus Advagraf as the primary immunosuppressive therapy. The model was 
able to estimate the effects of different proportions of patients with high or low within patient 
tacrolimus variability on longer-term graft loss outcomes based on two studies [Wu et al., 2011; 
Borra et al., 2010]. The underlying rate of graft failure was based on NHSBT data on renal 
transplant recipients in the UK. Cost data were taken from the British National Formulary and 
2012–2013 NHS tariff information. Deterministic and probabilistic sensitivity analyses were 
conducted to assess the robustness of the model results. 
 
The results of the analysis showed a mean per-patient cost (including tacrolimus, concomitant 
immunosuppressive medications, dialysis after graft failure, and treatment for acute rejection) 
was GBP 26,941 (standard deviation [SD] = GBP 2765) with PR tacrolimus vs. GBP 30,356 (SD 
= GBP 3085) for IR tacrolimus over a 5-year period, corresponding to a saving of GBP 3415 
(SD = GBP 516) per patient. 
 
5.2.2 Evaluation of the Study 
 
This study demonstrated that over a 5-year time horizon, using Advagraf, a prolonged-release 
tacrolimus formulation in renal transplant recipients could result in substantial cost savings in the 
UK healthcare system relative to immediate-release tacrolimus. Cost savings were driven 
primarily by a reduction in the incidence of graft failure in patients with lower within-patient 
variability, of which there were more in the prolonged-release arm than the immediate-release 
arm , 96.9% of patients in the prolonged- release arm vs. 82.6% in the immediate-release arm 
[Wu et al., 2011].  
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This study has a number of strengths and limitations. Key strengths include the use of simple 
and transparent modelling approach together with UK specific data for underlying graft loss and 
up to date UK cost data at time of publication.  
 
Another strength of the study is that this analysis was the first to factor within-patient variability 
data into an evaluation of the budgetary implications of post-renal transplant 
immunosuppression, and was the first UK, budget impact analysis of immunosuppressive agents 
ever to be published in peer-reviewed journals. The modelling approach used to link 
pharmacokinetic data to outcomes is a unique and great development which provides a 
framework for other therapeutic areas to utilise in their economic analysis.  Furthermore, the 
analysis has contributed to knowledge in this field and addressed the gaps that existed in 
literature.  
 
The main limitation of this study is that no long-term data were available to directly demonstrate 
differences in graft loss between patients on Advagraf relative to Prograf. The modeling analysis 
therefore utilised two data sources  one on the proportions of patients on Advagraf and Prograf 
with high within patient variability [Wu et al., 2011], and modeled these data with previously-
published evidence on the increased risks of graft loss associated with high within patient 
variability [Borra et al., 2010]. The use of two different studies with different patient populations 
to model outcomes could impact the certainty of the results. To mitigate for this heterogeneity 
of data sources, probabilistic sensitivity analysis was conducted in the base case sampling from 
distributions of key model parameters including graft failure risk, body weight, tacrolimus and 
concomitant medicines dosing. In addition, a number of one way sensitivity analyses were 
conducted. The results confirmed the model was robust whilst the magnitude of the savings 
changed the direction of the savings remained the same in favour of Advagraf.  
 
5.2.3 Conclusion 
 
This study demonstrated that, relative to IR tacrolimus, PR tacrolimus is cost-saving in renal 
transplant recipients in the UK. Savings were driven primarily by the lower costs associated with 
dialysis after graft failure which is lower with PR tacrolimus relative IR tacrolimus. PR tacrolimus 
therefore, offers both clinical (reduced graft failure) and economic (cost savings) benefits to renal 
transplant recipients and payers in the UK. Based on the results of this study PR tacrolimus 
should be considered as an alternative to the IR tacrolimus the current SoC in the UK. This 
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study presented a BIA based on within patient variability the next study will examine a budget 
impact analysis based on adherence to immunosuppression therapy. 
 
 
5.3  Muduma G, Odeyemi I, Smith-Palmer J, Pollock R. Budget Impact of switching from 
an Immediate-Release to a Prolonged-Release formulation of tacrolimus in Renal Transplant 
Recipients in the UK based on differences in Adherence. Patient Preference and Adherence. 
2014; 8: 391-9. (Publication 7) 
 
5.3.1 Description of the study 
 
Similar to the previous paper the development of this study was driven primarily by lack of 
budget impact analyses to inform payer decision making and the availability of data on the 
improvements in patient adherence observed with prolonged-release tacrolimus (Advagraf)  
relative to immediate-release tacrolimus (Prograf). Advagraf is associated with improved 
adherence compared with Prograf [Kuypers et al., 2013], which may ultimately improve long-
term graft survival outcomes. This study evaluated the budget impact of switching patients from 
Prograf to Advagraf in the UK based on patient adherence rates to immunosuppression. 
 
An Excel-based cohort model was developed to model rates of renal graft failure in patients 
prescribed Prograf versus Advagraf as the primary immunosuppressive therapy. The model was 
able to estimate the effects of different rates of patient adherence on longer-term graft loss 
outcomes using published data. Different proportions of adherent patients in the Prograf and 
Advagraf arms were taken from a randomised controlled trial by Kuypers et al., [2013] and risk 
of graft failure from an earlier study [Butler et al., 2004]. Similar to previous publication 6 (section 
5.2.2) study utilised the same methodology in terms of underlying rate of graft failure, cost data, 
time horizon, discounting and sensitivity analyses. 
 
The results of the analysis over a 5-year time horizon, showed the mean cost per patient 
(including tacrolimus, concomitant immunosuppressive medications, dialysis after graft failure, 
and treatment for acute rejection) was £29,328 (standard deviation [SD] £2,844) for Advagraf 
versus £33,061 (SD £3,178) for Prograf. The total cost saving of £3,733 (SD £530) was driven 
primarily by reduced dialysis costs arising from the lower incidence of graft failure (21.6% with 
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Prograf versus 18.3% with Advagraf) in the larger proportion of adherent patients in the 
Advagraf arm.  
 
 
 
5.3.2  Evaluation of the study 
 
This study showed that, relative to immediate-release tacrolimus, using prolonged-release 
formulation in renal transplant patients could result in substantial cost savings in the UK 
healthcare system over 5 years. This analysis has the same strengths as the previous study 
highlighted in (section 5.2.2). In addition, the specific strength of this study is that these analyses 
were the first to factor patient adherence data into an evaluation of the budgetary implications of 
post-renal transplant immunosuppression, and were the first adherence budget impact analysis of 
immunosuppressive agents ever to be published in peer-reviewed journals. 
 
The proportion of patients’ adherent to treatment with immediate-release versus prolonged-
release tacrolimus formulations was a key driver of the modelling analysis. The Kuypers et al., 
[2013] study adherence data used in this analysis was recently corroborated by a prospective 
observational study reported by [Sabbatini et al., 2014]. This gives credibility to the data 
supporting the economic analysis strengthening the findings of the model. However, there is a 
need to design a study with long-term follow up to assess the impact of adherence on graft loss 
in the same patient population to validate these results. 
 
As with the previous study publication 6 highlighted in section (5.2.2), the most notable 
limitation of this analysis was the lack of long term graft survival data from a single source. No 
long-term data were available to directly demonstrate differences in graft loss between patients 
immunosuppressed with Advagraf versus Prograf. The modeling analysis therefore utilised data 
on the different rates of patient adherence on Advagraf and Prograf [Kuypers et al., 2013] and 
modeled these data with previously published evidence on the increased risks of graft loss 
associated with non-adherence [Butler et al., 2004]. These two studies are different in terms of 
the primary immunosuppressant used for instance in Butler et al., [2004] the majority of patients 
were taking either ciclosporin or azathioprine unlike the Kuypers et al., [2013] study in which all 
patients were on Advagraf or Prograf. The linking of outcomes from these two studies could 
therefore, be challenged. Acknowledging this limitation probabilistic sensitivity analysis was 
conducted in the base case. In addition, a series of one way sensitivity analyses were conducted 
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including varying the rates of adherence between Advagraf and Progaf arms and altering the 
relative risk of graft failure. None of these analyses changed the direction of cost-saving of 
Advagraf relative to Prograf. However, the size of the cost savings was reduced.  
 
Another potential shortcoming of this study is around the limited outcomes captured. For 
example, Pinsky et al., [2009] reported significant variations in the incidence of mortality up to 3 
years after transplant, across patients divided into quartiles by first-year adherence to their 
immunosuppressive regimen. In the study, patient mortality in the “excellent” adherence group 
was 3.0% compared with 5.4% in the “fair” compliance group (p = 0.0001) [Pinsky et al., 2009] 
Despite this evidence, this study assumed no difference in mortality either between Prograf and 
Advagraf or between adherent and non-adherent patients. The primary justification for this was 
the implication of capturing mortality in a budget impact model, namely that a comparator 
associated with an increased risk of mortality would appear to be cheaper, while the reduction in 
life expectancy would not be captured in the model. Cost-effectiveness analyses, in which 
incremental costs are balanced with incremental effectiveness outcomes such as life expectancy, 
are better suited to capturing differences in mortality as discussed in chapter 4. 
 
5.3.4 Conclusion  
 
 This study demonstrated that conversion of renal transplant recipients from Prograf to 
Advagraf was associated with lower pharmacy and dialysis costs, with the reduction in dialysis 
costs being driven by improved adherence to Advagraf regimen and the consequent 
improvement in graft survival. This analysis suggests that Advagraf is a clinically and 
economically prudent choice for immunosuppression in renal transplant recipients in the UK. 
These findings could influence the development and or review of post-renal transplant 
immunosuppression local formularies, clinical and reimbursement guidelines at a national level.   
 
This study evaluated budget impact due to adherence. The next study will present a budget 
impact analysis based on AbMR due to non-adherence in post renal transplant. 
 
5.4 Muduma G, Odeyemi I, Pollock RF. Evaluating the Economic Implications of Non 
Adherence and Antibody -Mediated Rejection in Renal Transplant Recipients: The Role of 
Once-Daily, Prolonged-Release Tacrolimus in the UK setting. Journal of Medical 
Economics 2015; 18(12): 1010-20. (Publication 8) 
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5.4.1 Description of the Study 
 
The development of the antibody-mediated rejection (AbMR) budget impact model was started 
to address the lack of data on the economic implications of non-adherence and the resulting 
increase in AbMR and graft loss, as reported in [Sellarés et al., 2012]. This analysis builds on the 
previous study (Publication 7) by including data linking non adherence with AbMR. While short-
term kidney graft survival has gradually improved over time, improvements in long-term graft 
survival have been more modest. One key clinical factor limiting improved longer-term 
outcomes is AbMR, the incidence of which appears to be higher in patients who are non-
adherent to immunosuppressants. The aim of this study was to model the incidence and 
economic consequences of graft loss and AbMR in patients taking prolonged-release (PR) 
tacrolimus (Advagraf) compared to immediate-release (IR) tacrolimus (Prograf) from a UK, 
NHS payer perspective. 
 
A combined decision tree and four-state Markov model was developed which included the 
following health states: functioning graft, functioning graft with AbMR, dialysis after failed graft, 
and death. The model estimated the incidence of graft failure, AbMR and mortality in renal 
transplant recipients taking PR vs. IR tacrolimus. The underlying rates of graft failure were based 
on data from the NHSBT, while differential rates between Advagraf and Prograf were driven by 
the proportion of patients adherent to each regimen [Kuypers et al., 2013] and the increased risk 
of AbMR and graft failure in non-adherent patients reported by [Sellarés et al., 2012]. Cost data 
were taken from the British National Formulary and National Health Service reference costs and 
reported in 2014 pounds sterling.  
 
Modelling results showed that improved adherence would be associated with reduced incidence 
of AbMR, graft failure and health resource utilisation in renal transplant recipients. Based on 
improvements in adherence resulting from switching from IR to PR tacrolimus, the modelling 
analysis projected cost savings of GBP 4862 per patient over 5 years with Advagraf relative to 
Prograf, on absolute costs of GBP 40,974 and GBP 45,836, respectively. 
 
5.4.2 Evaluation of the study 
   
This study demonstrated that using Advagraf, a prolonged-release tacrolimus formulation in 
renal transplant recipients could result in substantial cost savings in the UK healthcare system 
  
53 
 
relative to immediate-release tacrolimus. In terms of contribution to knowledge this analysis was 
the first to evaluate the economic implications of non-adherence and AbMR in renal transplant 
recipients and the role of once-daily PR tacrolimus in the UK healthcare system.   
 
This analysis has the same strengths as Publication 6 (highlighted in section 5.2.2). In addition 
the specific strength of this study is that this analysis was the first to establish the costs 
associated with various AbMR treatment regimens in the UK setting, including treatment based 
on the Edinburgh Renal Unit (ERU) AbMR treatment protocol, and the ERU treatment 
protocol in combination with rituximab, eculizumab and botezomib infusions. The study 
highlighted that the lack of recognition of AbMR as a treatable indication had led to a lack of 
data on the efficacy of different treatment options. 
 
Similar to the previous BIA Publications 6 and 7 the key limitation of this analysis was the lack 
of long-term clinical outcomes data and use of different data sets to bridge this gap. This 
included using data from an RCT for the proportion of patients' adherent to once-daily versus 
twice-daily tacrolimus formulations by Kuypers et al., [2013], and data from Sellares et al., [2012] 
for the relative risk of graft failure and AbMR in non-adherent patients relative to adherent 
patients. Similar to previous publications 6 and 7 both probabilistic and deterministic analyses 
were conducted to mitigate uncertainty that may arise from use of heterogeneous data sets. A 
number of one way sensitivity analyses were performed around graft failure risk, AbMR 
treatment modality, patient mortality and time horizon. The results confirmed the model to be 
robust. However, the sensitivity analyses showed that the incidence of AbMR had significant 
impact on absolute cost savings indicating that therapies with lower incidence of AbMR would 
yield greater cost savings suggesting Advagraf should be the tacrolimus formulation of choice.  
 
5.4.3 Conclusion 
 
This study has demonstrated that Advagraf would be cost-saving relative to Prograf in renal 
transplant recipients in the UK setting, with cost savings driven by reduced costs associated with 
dialysis, treatment of AbMR, and primary immunosuppressive medication. This analysis suggests 
that Advagraf may reduce the incidence of AbMR in UK renal transplant recipients and 
therefore, represent a clinically and economically appropriate choice for immunosuppression in 
renal transplant recipients in the UK. The key implication here is that UK, local and national 
payers might now consider funding Advagraf ahead of Prograf due to its clinical and economic 
benefits. 
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5.6 Chapter Summary 
 
This chapter presented three studies evaluating the budget impact analysis of immediate-release 
tacrolimus (Prograf) compared with prolonged-release tacrolimus (Advagraf) in post-renal 
transplantation immunosuppression therapy from a UK, NHS payer perspective. Each study 
made a significant contribution to knowledge in this field and hence addressing the gap in 
literature. The results across the three studies suggest that Advagraf is clinically effective in terms 
of graft survival and cost saving compared with Prograf in post renal transplant 
immunosuppression from a UK setting. However, the key limitation of these analyses was the 
heterogeneity of the clinical data used to model graft loss for example data on within patient 
variability and risk of graft loss was taken from two different trials with different patient 
population and hence uncertainty around the results. The key implication of these BIAs is that 
they can now be used in the UK and after  adaptation can be utilised with other countries to 
inform local payers funding, formulary and product adoption which consequently impact patient 
access to immunosuppressive medicines. The next chapter presents a summary, conclusions and 
recommendations of the thesis. 
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Chapter 6: Summary, Conclusions  and Recommendations 
 
6.1 Summary 
 
Globally the number of patients living with renal and liver transplantation is increasing. The 
prevalence, clinical and economic burden of ESRD and ESLD leading to the need for 
transplantation and effective immunosuppression therapy to ensure patient and graft survival 
was highlighted in Chapter 2 of the thesis. Given the need for constant immunosuppression in 
these patients the clinical and economic impact of immunosuppressive regimens should be 
established and periodically reviewed to ensure that patient and graft survival are optimised and 
payers are making the best use of increasingly strained healthcare budgets. 
 
The aim of the thesis was to evaluate the clinical and economic impact of immunosuppressive 
therapy in the treatment and management of adult renal and liver transplant recipients. Through 
the presentation and critical review of eight publications, the clinical and cost effectiveness 
together with the budget impact analysis of immunosuppression therapy was assesed. Each paper 
was used to demonstrate the clinical and or economic impact of immunosuppression therapy to 
patients, payers and healthcare decision makers. The thesis highlights how the eight publications 
have formed a cohesive body of evidence which can be used by policy makers to inform the 
development and or updating of clinical and reimbursement guidelines which ultimately impact 
patients access to  immunosuppression therapy. The findings of this research provides clinical 
and economic evidence supporting the use of prolonged release, once daily tacrolimus 
(Advagraf) as the cornerstone of primary immunosuppressive therapy in liver and renal 
transplant recipients. However, further research is needed to establish the long term clinical 
effectiveness of immunosuppression in renal and liver transplantation. 
 
This chapter examines the contribution of the research, reviews the implications and limitations 
of the thesis and highlights recommendations for future research. 
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6.2 Contribution to Research 
 
Chapter 3, examined the relative effectiveness of immunosuppressive therapy used in adult renal 
and liver transplant. The two publications presented in this chapter described an update on 
immunosuppressive clinical effectiveness evidence in adult post renal and liver transplantation 
which added knowledge to the field. The Indirect treatment comparison of belatacept versus 
tacrolimus in renal transplant immunosuppression was the first ITC analysis comparing 
tacrolimus formulations with both belatacept more intense and less intense dosing regimens to 
be published in a peer reviewed journal updating research in this field. Equally, the systematic 
review and meta-analysis of tacrolimus versus ciclosporin as primary immunosuppression after 
liver transplant updated evidence in this area. This meta-analysis was the first study of post-
transplant immunosuppression in liver transplant recipients conducted based exclusively on 
RCTs published since 2000, representing the most recent available data and therefore reflecting 
current clinical practice and modern liver transplant era.  
 
Chapter 4, presented three articles which summarised and critiqued the approach taken in the 
development of cost utility and effectiveness analyses in renal and liver post–transplant 
immunosuppression. The studies provided new knowledge and significant update on economic 
analyses of post renal and liver transplant immunosuppression therapy.  The Cost utility analysis 
of immunosuppressive regimens in adult renal transplant recipients in England and Wales 
represented the first cost-utility analysis to be published on post-renal transplant 
immunosuppression that captured the effects of patient adherence specifically to tacrolimus 
formulations. Furthermore, the analysis represents a significant update to the health economic 
evidence base in renal post-transplant immunosuppression in the UK since the publication by 
Woodroffe et al., [2005]. The Cost-utility analysis of prolonged-release tacrolimus relative to 
immediate-release tacrolimus and ciclosporin in liver transplant recipients in the UK was the first 
health economic analysis to be conducted in this area and hence adding new knowledge in this 
field. Similarly, the cost-effectiveness of prolonged-release tacrolimus relative to immediate-
release tacrolimus in liver transplant patients represented the first within-trial analysis of cost 
effectiveness in liver transplant recipients using routine clinical practice data and hence 
generating new knowledge. 
 
Chapter 5, presented three studies which evaluated the budget impact analysis of immediate-
release tacrolimus compared with prolonged-release tacrolimus in post-renal transplantation 
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immunosuppression therapy from a UK, NHS payer perspective. These were the first post-renal 
transplant immunosuppression BIAs in the UK to be published in peer reviewed journals.  Each 
study made a valuable contribution to knowledge in this field and also addressed a significant gap 
in literature which existed prior to the publication of these studies. 
 
 
6.3 Implications of the Thesis 
 
This research represent a well integrated body of work the ultimate objective which was to 
demonstrate the clinical and economic impact of immunosuppression therapy with a view to 
recommending the most effective immunosuppressive product(s) for renal and liver transplant 
recipients. Prior to 2013, no health economic evaluation on immunosuppressive therapy was 
done in liver transplantation in the UK. The renal economic analysis was dated with the last 
evaluation published by Woodrofee et al., [2005] and no budget impact analyses had been 
published in renal transplant. The clinical effectiveness data was also limited to old products and 
clinical trials in both renal and liver transplant as the previous meta-analyses lacked comparison 
of newer immunosuppressive products and formulations from recent RCT data.  
 
This body of work utilised a broad range of clinical evidence, including SLR, ITC, NMA and 
routine clinical practice data for comparative effectiveness. A number of modelling approaches 
were also employed to demonstrate the clinical and economic impact of immunosuppression 
therapy in post renal and liver transplant patients. The thesis provides an example to other 
therapuetic areas on how to update and generate new evidence using widely accepted evidence 
generation and synthesis methodologies. Importantly, the economic models presented in this 
thesis though from a UK perspective they can be adapted to other healthcare systems potentially 
impacting reimbursement guidelines and consequently patient access to immunosuppression in 
other countries. The clinical evidence generated from this thesis is transferable across healthcare 
systems and therefore, could be used to influence and inform reimbursement policies, clinical 
guidelines and practice in the UK and healthcare systems across the world. Consequently, 
impacting renal and liver transplant patients access to immunosuppression therapy and 
improvement in their survival and quality of life in a cost effective way. 
 
Another key implication for the thesis is centred around the budget impact analyses of 
immunosuppressive therapies. Basically, budget impact analysis provides useful information to 
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tackle the new hurdle of affordability, after having fulfilled the better-known hurdles of added 
clinical value of new treatments over existing ones [Marshall et al., 2008; Orlewska and 
Mierzejewski, 2004]. In this regard BIA is key in terms of product adoption and patient access to 
medicine. Therefore, the BIAs in this research can be used in the UK to inform local payers 
formulary and product adoption decisions. Unlike CEA which can be used for priority setting at 
a national level. The BIA can be used for assessing affordability and sustainability at a local level 
in line with the health economy budgets. The BIA in this thesis after adaptation can be used as a 
template by payers in other countries to inform their reimbursement, formulary and adoption 
decisions at a national, regional and local level. Therefore, the BIAs in this thesis have the 
potential to influence reimbursement and formulary decisions in the UK and other healthcare 
systems across the world. Consequently impacting renal transplant patients access to 
immunosuppressive medicines. 
 
6.4 Limitations of the Thesis 
 
This thesis has presented an update and generated new data on immunosuppression therapy 
clinical and cost effectiveness evidence in post renal and liver transplant recipients. As discussed 
above in section 6.2 this research has addressed a gap that existed in literature at the same time 
contributing to new knowledge in the field. However, there are limitations of the thesis that need 
to be acknowledged. Firstly regarding cost effective analyses all the economic studies presented 
in this thesis were conducted from a healthcare payer perspective. This approach excludes a 
number of important societal aspects such as productivity costs for example time lost from 
work, out of pocket expenses for the patient, family and friends. Both renal and liver transplant 
are associated with significant loss of productivity. Therefore, a societal perspective would have 
captured all relevant costs and benefits to society as a whole regardless of the source of 
immunosuppression funding. It can therefore, be argued that the economic evaluations 
presented in this thesis provide a conservative estimate of the costs and benefits that can be 
realised at a societal level since payer perspective does not include all relevant costs and benefits 
in their analyses.  
 
Secondly,  most of the data used to inform the relative clinical effectiveness is based on meta-
analyses of RCTs. The RCT data presented in this thesis is derived from 12 month outcomes 
data which is then extrapolated for the rest of the economic model time horizon. However, the 
RCT data might not reflect what happens in routine clinical practice in the long term as the 
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disease evolves such as future complications and more importantly benefits in the form of 
improved productivity and or patient quality of life. Due to the limited treatment and follow up 
period,  economic  models based on RCT data risk missing important effects of transplantation 
in the long-term which could have significant economic implications. This can be addressed by 
conducting real world studies with a long-term follow up to capture what actually happens in 
routine clinical practice. 
Thirdly, the economic evaluations did not include any sub-group analysis. Patient and disease 
characteristics such as severity and comorbidities are expected to influence cost effectiveness and 
therefore it is important to conduct evaluations in different population subgroups [Studer et al., 
2004]. This limitation is more specific to the Muduma et al., [2016] cost utility analysis in which 
the model was restricted to liver transplant patients with non-recurrent indications. 
 
Finally, the economic models included in the present thesis excluded costs associated with 
adverse events of immunosuppression therapy such as hypertension and NODAT. This was due  
to lack of data to provide informative estimates on the risk of these adverse events in particular 
with prolonged release tacrolimus. Relatedly, due to lack of data none of the economic models 
incorporated treatment switches due to patients changing therapy as a result of either adverse 
effects or lack of therapuetic effect that you could expect to see in routine clinical practice. 
Therefore, there is need to collect RWE on both treatment switches and adverse events across 
all the relevant immunosuppresion therapies. This data could be incorporated into the economic 
models to reflect what happens in routine clinical practice and hence address the generalisability 
and relevance of these results to patients and payers respectively. 
 
In respect of clinical effectiveness the data generated from ITC and meta-analyses is derived 
from RCTs which limits the generalisability of results. Due to the stringent inclusion/exclusion 
criteria the samples in the RCTs may not be reflective of the the general transplant population in 
routine clinical practice. Consequently, it can be argued that you cannot apply the findings of 
these analyses to the general transplant population. Also as already mentioned the RCT data is 
limited to 12 months outcomes and hence not reflective of what could happen in the long-term. 
Again this could be addresed by collecting longitudinal RWE which is in line with payer 
requirements [Stegenga et al., 2017].  
 
6.5 Recommendations for Further Research 
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Based on the findings from this thesis a number of recommendations can be made as to where 
future research should be centered to further augment our understanding of the clinical and 
economic impact of immunosuppression therapy in adult renal and liver transplant recipients. 
With respect to clinical effectiveness presented in Chapter 3. Most of the comparative clinical 
effectiveness data is based on RCTs. However, as discussed above (section 6.4) this data has 
some limitations, notably the protocol driven nature of RCTs, short follow up time, small and 
highly selected sample. Consequently, there might be issues in terms of the generalisability of this 
data to the renal and liver post-transplant population in routine clinical practice. In addition, the 
outcomes from the RCT data might not reflect what happens in the real world in the long-term 
as the disease evolves. Therefore, there is need to conduct real world studies in both post renal 
and liver transplant recipients. The studies could take the form of either a prospective routine 
clinical practice study or retrospective database analysis. However, the latter might be limited in 
terms of the data captured in the databases. RWE using longitudinal studies would provide an 
opportunity to gather long-term clinical and economic outcomes of immunosuppression therapy 
in routine clinical practice mitigating the limitations of RCT data. However, it should be pointed 
out that studies that generate RWE are less statistically rigorous than RCTs with inadvertent 
biases [Stegenga et al., 2017]. This could be addressed by integrating RWE with RCT data for 
example in post liver transplantation where there is emerging routine clinical data comparing 
tacrolimus formulations [Adam et al., 2015]. Recent studies have reported quantitative 
approaches to combining data from randomized and non-randomized studies using Bayesian 
hierarchical models and adjusting study estimates for potential confounders using differences in 
patient characteristics between study arms [McCarron et al., 2010]. This could provide an avenue 
for further research on the relative clinical effectiveness of ciclosporin and tacrolimus 
formulations in renal transplant recipients. There is currently ongoing research of this nature in 
post liver transplant, which the present author is contributing to. This research would ensure 
comparison of all key primary immunosuppression therapies and also incorporation of all 
relevant available clinical data from both RCT and observation studies which would make the 
results more comprehensive, robust, generalisable and informative for payers.   
 
In order to address the lack of direct comparisons and long term outcomes among the 
competing interventions in both renal and liver transplantation. It is recommended that direct 
head to head RCTs with long term follow up be conducted comparing the primary 
immunosuppression in both renal and liver focusing on the key outcomes discussed in this 
thesis. This would address to a certain extent the dosing issue and also provide new data on 
  
61 
 
outcomes to add to the current meta-analyses and ITC making the body of evidence more 
robust. 
 
Regarding cost effectiveness presented in Chapter 4. In many areas of medicine, the costs in the 
year prior to significant clinical events rise substantially [Hwang 2009; Tanuseputro 2015; Geue 
2014]. In the UK the costs of transplantation are well established [NHS, 2016]. However, 
knowledge about the healthcare resource utilisation and associated costs during the last year 
before graft failure for kidney or liver transplant patients are limited. The health economic 
studies presented in this thesis and those in the literature to date do not include the cost 
associated with graft loss. Traditionally, economic evaluations in the field of transplantation have 
taken into consideration potential changes in post-transplantation costs [Jurgensen, et al. 2010]. 
However, cost variations using graft failure as the index date have generally not been accounted 
for in economic models. Therefore, it is recommended that observational studies be undertaken 
to estimate the total cost of healthcare resource use (HRU) observed in the year prior to the date 
of kidney or liver transplant failure.  
 
These HRU data prior to kidney or liver transplant failure would be of use for input into 
economic evaluations of kidney or liver immunosuppression where so far little attention has 
been paid to the costs incurred in year prior to graft failure. This would help in capturing the true 
cost associated with graft loss. There are likely to be significant cost-saving implications for 
immunosuppression therapy that can be shown to delay the time to graft failure. The present 
author conceived research which is on-going on HRU and costs associated with graft loss in 
both renal and liver transplant. When completed this research would greatly improve current 
economic models by integrating this data into the post-transplant immunosuppression economic 
evaluations making the analyses more comprehensive and useful for payers as they capture these 
significant costs which have an implication on a health economy budget. 
 
The accuracy of the cost effectiveness analyses presented in this thesis could be improved if 
updated with routine clinical practice data with longitudinal dosing data. This has been 
highlighted as a source of uncertainty in current studies. Finally, there is a great opportunity to 
further develop the economic models to include subgroup analysis for example in patients with 
recurrent conditions particularly HCC and HCV in post liver transplantation. Future studies 
should also try to expand on existing studies by taking a societal perspective, including more 
costs and benefits in their analyses. 
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6.6 Conclusions 
 
In conclusion, the research presented in this thesis has demonstrated that tacrolimus is the most 
cost and clinically effective treatment in both renal and liver transplant recipients. Specifically, 
Advagraf the once-daily prolonged release tacrolimus formulation has been shown to be 
clinically and economically more effective than the current standard of care Prograf, twice-daily 
immediate release tacrolimus formulation. Advagraf was more cost and clinically effective 
relative to Prograf from a UK, payer perspective. A finding that is likely to influence clinical and 
reimbursement guidelines for post renal and liver transplant immunosupression in the UK. The 
discussed clinical evidence limitations of this research can be addressed through the design of an 
RCT with a long term follow up comparing all the key immunosuppression therapies that is 
tacrolimus, ciclosporin and belatacept.  
 
This should be complemented by a routine clinical practice data analysis in the form of a 
longitudinal observational study capturing patient and graft survival, NODAT, renal dysfunction, 
hypertension, AbMR, and dosing regimes in the real world. These studies should be conducted 
in both renal and liver transplant. Finally, economic analyses could be improved by taking a 
societal perspective, incorporating costs associated with graft failure, and use of real world data 
in economic models comparing all relevant interventions.  
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